ID	start_index	end_index	token	lemma	POS
1	24	36	Introduction	introduction	NNP
2	45	48	The	the	DT
3	49	56	concept	concept	NN
4	57	59	of	of	IN
5	60	64	lung	lung	NN
6	65	76	fibroblasts	fibroblast	NNS
7	77	79	as	as	IN
8	80	88	effector	effector	NN
9	89	94	cells	cell	NNS
10	95	97	in	in	IN
11	98	101	the	the	DT
12	110	122	pathogenesis	pathogenesis	NNS
13	123	125	of	of	IN
14	126	136	idiopathic	idiopathic	JJ
15	137	146	pulmonary	pulmonary	JJ
16	147	155	fibrosis	fibrosis	NNS
18	157	160	IPF	ipf	NNP
20	162	165	has	have	VBZ
21	174	182	recently	recently	RB
22	183	190	evolved	evolve	VBN
24	193	194	1	1	CD
25	195	196	2	2	CD
28	201	205	Lung	lung	NNP
29	206	217	fibroblasts	fibroblast	NNS
30	218	225	respond	respond	VBP
32	236	238	in	in	IN
33	239	244	vitro	vitro	NN
35	247	249	to	to	TO
36	250	262	inflammatory	inflammatory	JJ
37	263	272	cytokines	cytokine	NNS
38	281	283	by	by	IN
39	284	293	producing	produce	VBG
40	294	300	growth	growth	NN
41	301	308	factors	factor	NNS
42	309	312	and	and	CC
43	313	321	collagen	collagen	NN
45	323	332	resulting	result	VBG
46	333	335	in	in	IN
47	344	354	fibroblast	fibroblast	NN
48	355	368	proliferation	proliferation	NN
49	369	372	and	and	CC
50	373	386	extracellular	extracellular	NN
51	387	393	matrix	matrix	NN
52	402	412	deposition	deposition	NN
54	415	416	2	2	CD
55	417	418	3	3	CD
56	419	420	4	4	CD
59	425	427	In	in	IN
60	428	436	addition	addition	NN
62	438	447	activated	activate	VBN
63	448	452	lung	lung	NN
64	461	472	fibroblasts	fibroblast	NNS
65	473	477	have	have	VBP
66	478	482	been	be	VBN
67	483	488	shown	show	VBN
68	489	491	to	to	TO
69	492	499	produce	produce	VB
70	500	505	large	large	JJ
71	506	513	amounts	amount	NNS
72	514	516	of	of	IN
73	525	537	inflammatory	inflammatory	JJ
74	538	547	cytokines	cytokine	NNS
75	548	551	and	and	CC
76	552	562	chemokines	chemokine	NNS
78	573	575	in	in	IN
79	576	581	vitro	vitro	NN
81	584	587	and	and	CC
82	588	593	hence	hence	RB
84	595	600	these	these	DT
85	601	606	cells	cell	NNS
86	607	610	may	may	MD
87	619	623	also	also	RB
88	624	628	have	have	VB
89	629	630	a	a	DT
90	631	635	role	role	NN
91	636	638	as	as	IN
92	639	647	effector	effector	NN
94	648	660	inflammatory	inflammatory	JJ
95	661	666	cells	cell	NNS
97	669	670	1	1	CD
98	671	672	2	2	CD
101	685	689	This	this	DT
102	690	698	capacity	capacity	NN
103	699	701	to	to	TO
104	702	709	produce	produce	VB
105	710	714	both	both	DT
106	715	727	inflammatory	inflammatory	JJ
107	728	731	and	and	CC
108	732	740	fibrotic	fibrotic	JJ
109	749	756	factors	factor	NNS
110	757	762	could	could	MD
111	763	767	mean	mean	VB
112	768	772	that	that	IN
113	773	787	phenotypically	phenotypically	RB
114	788	795	altered	alter	VBN
115	796	800	lung	lung	NN
116	809	820	fibroblasts	fibroblast	NNS
117	821	824	act	act	VBP
118	825	839	simultaneously	simultaneously	RB
119	840	842	as	as	IN
120	843	851	effector	effector	NN
121	852	855	and	and	CC
122	856	862	target	target	NN
123	871	876	cells	cell	NNS
125	878	881	via	via	IN
126	882	891	paracrine	paracrine	NN
127	892	895	and	and	CC
128	896	905	autocrine	autocrine	NN
129	906	916	mechanisms	mechanism	NNS
131	918	930	perpetuating	perpetuate	VBG
132	939	942	the	the	DT
133	943	951	fibrotic	fibrotic	JJ
134	952	959	process	process	NN
136	962	963	2	2	CD
139	976	987	Prostanoids	prostanoids	NNP
140	988	991	are	be	VBP
141	992	1001	important	important	JJ
142	1002	1012	regulators	regulator	NNS
143	1013	1015	of	of	IN
144	1016	1026	fibroblast	fibroblast	NN
145	1035	1043	function	function	NN
147	1046	1047	5	5	CD
148	1048	1049	6	6	CD
149	1050	1051	7	7	CD
150	1052	1053	8	8	CD
151	1054	1055	9	9	CD
154	1060	1073	Prostaglandin	prostaglandin	NNP
156	1075	1077	PG	pg	NNP
159	1089	1090	2	2	CD
160	1091	1093	is	be	VBZ
161	1094	1101	thought	think	VBN
162	1102	1104	to	to	TO
163	1105	1109	have	have	VB
164	1110	1122	antifibrotic	antifibrotic	JJ
165	1131	1141	properties	property	NNS
166	1151	1153	in	in	IN
167	1154	1159	vitro	vitro	NN
169	1162	1165	but	but	CC
170	1166	1170	also	also	RB
171	1171	1174	can	can	MD
172	1175	1179	have	have	VB
173	1188	1203	proinflammatory	proinflammatory	NN
174	1204	1211	effects	effect	NNS
175	1212	1216	both	both	DT
176	1226	1228	in	in	IN
177	1229	1233	vivo	vivo	NN
178	1234	1237	and	and	CC
179	1247	1249	in	in	IN
180	1250	1255	vitro	vitro	NN
182	1258	1260	10	10	CD
183	1261	1263	11	11	CD
184	1264	1266	12	12	CD
187	1271	1282	Thromboxane	thromboxane	NNP
189	1292	1294	TX	tx	NNP
192	1306	1307	2	2	CD
193	1308	1317	increases	increase	NNS
194	1318	1331	proliferation	proliferation	NN
196	1333	1336	and	and	CC
197	1337	1340	DNA	dna	NNP
198	1341	1344	and	and	CC
199	1353	1356	RNA	rna	NNP
200	1357	1366	synthesis	synthesis	NN
201	1367	1369	in	in	IN
202	1370	1377	several	several	JJ
203	1378	1382	cell	cell	NN
204	1383	1388	types	type	NNS
206	1390	1399	including	include	VBG
207	1400	1411	fibroblasts	fibroblast	NNS
208	1420	1423	and	and	CC
209	1424	1430	smooth	smooth	JJ
210	1431	1437	muscle	muscle	NN
211	1438	1442	like	like	IN
212	1443	1453	glomerular	glomerular	NN
213	1454	1463	mesangial	mesangial	NN
214	1464	1469	cells	cell	NNS
216	1472	1474	13	13	CD
217	1475	1477	14	14	CD
218	1486	1488	15	15	CD
219	1489	1491	16	16	CD
222	1496	1506	Conversely	conversely	RB
224	1508	1520	prostacyclin	prostacyclin	NN
226	1522	1525	PGI	pgi	NNP
227	1535	1536	2	2	CD
229	1539	1548	decreases	decrease	NNS
230	1549	1555	smooth	smooth	JJ
231	1556	1562	muscle	muscle	NN
232	1563	1567	cell	cell	NN
233	1576	1589	proliferation	proliferation	NN
234	1590	1593	and	and	CC
235	1594	1602	collagen	collagen	NN
236	1603	1612	synthesis	synthesis	NN
238	1615	1617	17	17	CD
239	1618	1620	18	18	CD
242	1633	1637	Many	many	JJ
243	1638	1642	cell	cell	NN
244	1643	1648	types	type	NNS
246	1650	1659	including	include	VBG
247	1660	1664	lung	lung	NN
248	1665	1676	fibroblasts	fibroblast	NNS
250	1678	1685	contain	contain	VB
251	1694	1708	cyclooxygenase	cyclooxygenase	NN
253	1710	1713	COX	cox	NNP
256	1716	1717	a	a	DT
257	1718	1726	proximal	proximal	NN
258	1727	1733	enzyme	enzyme	NN
259	1734	1736	in	in	IN
260	1737	1747	prostanoid	prostanoid	NN
261	1756	1766	production	production	NN
263	1768	1771	and	and	CC
264	1772	1775	can	can	MD
265	1776	1784	generate	generate	VB
266	1785	1796	prostanoids	prostanoid	NNS
268	1799	1801	19	19	CD
271	1806	1808	It	it	PRP
272	1809	1812	has	have	VBZ
273	1821	1825	been	be	VBN
274	1826	1836	previously	previously	RB
275	1837	1845	reported	report	VBN
276	1846	1850	that	that	IN
277	1851	1854	IPF	ipf	NNP
278	1855	1859	lung	lung	NN
279	1860	1871	fibroblasts	fibroblast	NNS
280	1872	1876	have	have	VBP
281	1885	1894	decreased	decrease	VBN
282	1895	1900	COX-2	cox-2	NNP
283	1901	1911	expression	expression	NN
284	1912	1920	compared	compare	VBN
285	1921	1923	to	to	TO
286	1924	1930	normal	normal	JJ
287	1931	1935	lung	lung	NN
288	1944	1955	fibroblasts	fibroblast	NNS
289	1956	1959	and	and	CC
291	1961	1966	hence	hence	RB
293	1968	1972	have	have	VBP
294	1973	1982	decreased	decrease	VBN
295	1983	1986	PGE	pge	NNP
296	1996	1997	2	2	CD
297	1998	2008	production	production	NN
299	2011	2013	12	12	CD
300	2014	2016	20	20	CD
301	2017	2019	21	21	CD
304	2024	2031	Because	because	IN
305	2032	2034	of	of	IN
306	2043	2048	these	these	DT
307	2049	2057	findings	finding	NNS
308	2058	2061	and	and	CC
309	2062	2065	the	the	DT
310	2066	2070	fact	fact	NN
311	2071	2075	that	that	IN
312	2076	2079	PGs	pgs	NNP
313	2080	2083	are	be	VBP
314	2084	2093	important	important	JJ
315	2102	2112	fibroblast	fibroblast	NN
316	2113	2123	regulators	regulator	NNS
318	2125	2127	we	we	PRP
319	2128	2134	sought	seek	VBD
320	2135	2137	to	to	TO
321	2138	2149	investigate	investigate	VB
322	2150	2157	whether	whether	IN
323	2166	2179	abnormalities	abnormality	NNS
324	2180	2182	in	in	IN
325	2183	2188	COX-2	cox-2	NNP
326	2189	2199	expression	expression	NN
327	2200	2205	could	could	MD
328	2206	2208	be	be	VB
329	2209	2219	associated	associate	VBN
330	2220	2224	with	with	IN
331	2233	2235	an	an	DT
332	2236	2243	altered	alter	VBN
333	2244	2251	balance	balance	NN
334	2252	2259	between	between	IN
335	2260	2271	profibrotic	profibrotic	JJ
336	2272	2275	and	and	CC
337	2276	2288	antifibrotic	antifibrotic	JJ
338	2297	2300	PGs	pgs	NNP
340	2302	2304	We	we	PRP
341	2305	2317	hypothesized	hypothesize	VBN
342	2318	2322	that	that	IN
343	2323	2334	fibroblasts	fibroblast	NNS
344	2335	2339	from	from	IN
345	2340	2343	the	the	DT
346	2344	2349	lungs	lung	NNS
347	2350	2352	of	of	IN
348	2361	2369	patients	patient	NNS
349	2370	2374	with	with	IN
350	2375	2378	IPF	ipf	NNP
352	2380	2386	HF-IPF	hf-ipf	NNP
354	2388	2392	have	have	VBP
355	2393	2395	an	an	DT
356	2396	2403	altered	alter	VBN
357	2404	2406	PG	pg	NNP
358	2407	2414	balance	balance	NN
359	2423	2431	compared	compare	VBN
360	2432	2434	to	to	TO
361	2435	2441	normal	normal	JJ
362	2442	2446	lung	lung	NN
363	2447	2458	fibroblasts	fibroblast	NNS
365	2460	2465	HF-NL	hf-nl	NNP
368	2468	2472	This	this	DT
369	2481	2493	phenotypical	phenotypical	JJ
370	2494	2505	abnormality	abnormality	NN
371	2506	2511	could	could	MD
372	2512	2514	be	be	VB
373	2515	2517	an	an	DT
374	2518	2527	important	important	JJ
375	2528	2534	factor	factor	NN
376	2535	2537	in	in	IN
377	2546	2549	the	the	DT
378	2550	2562	pathogenesis	pathogenesis	NNS
379	2563	2565	of	of	IN
380	2566	2569	IPF	ipf	NNP
382	2593	2602	Materials	material	NNS
383	2603	2606	and	and	CC
384	2607	2614	methods	method	NNS
385	2634	2641	Primary	primary	JJ
386	2642	2646	lung	lung	NN
387	2647	2658	fibroblasts	fibroblast	NNS
388	2669	2680	Fibroblasts	fibroblasts	NNP
389	2681	2685	from	from	IN
390	2686	2689	the	the	DT
391	2690	2695	lungs	lung	NNS
392	2696	2698	of	of	IN
393	2699	2704	seven	seven	CD
394	2705	2713	patients	patient	NNS
396	2715	2716	6	6	CD
397	2717	2722	males	male	NNS
399	2734	2738	with	with	IN
400	2739	2742	IPF	ipf	NNP
402	2744	2750	HF-IPF	hf-ipf	NNP
404	2752	2756	were	be	VBD
405	2757	2766	harvested	harvest	VBN
407	2768	2769	a	a	DT
409	2771	2775	from	from	IN
410	2776	2783	excised	excise	VBD
411	2784	2788	lung	lung	NN
412	2789	2791	at	at	IN
413	2802	2805	the	the	DT
414	2806	2810	time	time	NN
415	2811	2813	of	of	IN
416	2814	2818	lung	lung	NN
417	2819	2834	transplantation	transplantation	NN
421	2839	2845	during	during	IN
422	2846	2848	an	an	DT
423	2849	2856	autopsy	autopsy	NN
424	2867	2876	performed	perform	VBN
425	2877	2883	within	within	IN
426	2884	2885	4	4	CD
427	2886	2891	hours	hour	NNS
428	2892	2896	from	from	IN
429	2897	2902	death	death	NN
431	2904	2906	or	or	CC
434	2910	2916	during	during	IN
435	2917	2921	open	open	NN
436	2922	2924	or	or	CC
437	2935	2949	transbronchial	transbronchial	NN
438	2950	2954	lung	lung	NN
439	2955	2963	biopsies	biopsy	NNS
440	2964	2966	at	at	IN
441	2967	2970	the	the	DT
442	2971	2975	time	time	NN
443	2976	2978	of	of	IN
444	2979	2988	diagnosis	diagnosis	NN
446	2990	2992	Of	of	IN
447	3003	3006	the	the	DT
448	3007	3012	seven	seven	CD
449	3013	3021	patients	patient	NNS
451	3023	3027	five	five	CD
452	3028	3036	subjects	subject	NNS
453	3037	3040	had	have	VBD
454	3041	3049	advanced	advance	VBN
455	3050	3054	lung	lung	NN
456	3065	3073	fibrosis	fibrosis	NNS
457	3074	3077	and	and	CC
458	3078	3082	were	be	VBD
459	3083	3092	receiving	receive	VBG
460	3093	3103	prednisone	prednisone	NN
462	3116	3133	immunosuppressive	immunosuppressive	JJ
463	3134	3140	agents	agent	NNS
465	3142	3143	2	2	CD
466	3144	3152	patients	patient	NNS
467	3153	3157	were	be	VBD
468	3158	3160	at	at	IN
469	3161	3163	an	an	DT
470	3164	3171	earlier	earlier	JJR
471	3182	3187	stage	stage	NN
472	3188	3190	of	of	IN
473	3191	3196	their	their	PRP$
474	3197	3204	disease	disease	NN
475	3205	3208	and	and	CC
476	3209	3213	were	be	VBD
477	3214	3217	not	not	RB
478	3218	3227	receiving	receive	VBG
479	3238	3255	immunosuppressive	immunosuppressive	JJ
480	3256	3261	drugs	drug	NNS
482	3263	3266	The	the	DT
483	3267	3271	mean	mean	JJ
484	3272	3275	age	age	NN
485	3276	3278	of	of	IN
486	3279	3282	the	the	DT
487	3283	3291	patients	patient	NNS
488	3292	3295	was	be	VBD
489	3306	3308	59	59	CD
491	3310	3315	range	range	NN
492	3316	3318	43	43	CD
494	3319	3321	71	71	CD
498	3325	3330	HF-NL	hf-nl	NNP
499	3331	3335	were	be	VBD
500	3336	3344	cultured	cultured	JJ
501	3345	3349	from	from	IN
502	3350	3354	five	five	CD
503	3355	3360	human	human	JJ
504	3371	3376	lungs	lung	NNS
505	3377	3381	that	that	WDT
506	3382	3389	arrived	arrive	VBD
507	3390	3392	at	at	IN
508	3393	3396	our	our	PRP$
509	3397	3407	transplant	transplant	NN
510	3408	3414	center	center	NN
511	3415	3419	with	with	IN
512	3420	3423	the	the	DT
513	3434	3443	intention	intention	NN
514	3444	3446	of	of	IN
515	3447	3452	being	be	VBG
516	3453	3457	used	use	VBN
517	3458	3461	for	for	IN
518	3462	3477	transplantation	transplantation	NN
520	3479	3482	but	but	CC
521	3483	3486	for	for	IN
522	3497	3504	various	various	JJ
523	3505	3512	reasons	reason	NNS
524	3513	3518	could	could	MD
525	3519	3522	not	not	RB
526	3523	3525	be	be	VB
527	3526	3538	transplanted	transplant	VBN
529	3540	3545	these	these	DT
530	3546	3550	were	be	VBD
531	3561	3576	macroscopically	macroscopically	RB
532	3577	3580	and	and	CC
533	3581	3596	microscopically	microscopically	RB
534	3597	3603	normal	normal	JJ
536	3605	3608	The	the	DT
537	3609	3614	cells	cell	NNS
538	3625	3629	were	be	VBD
539	3630	3639	harvested	harvest	VBN
540	3640	3643	and	and	CC
541	3644	3652	cultured	cultured	JJ
542	3653	3655	as	as	IN
543	3656	3659	per	per	IN
544	3660	3663	the	the	DT
545	3664	3672	protocol	protocol	NN
546	3673	3682	described	describe	VBN
547	3693	3695	by	by	IN
548	3696	3701	Kumar	kumar	NNP
549	3713	3715	et	et	CC
550	3716	3719	al.	al.	NN
552	3722	3724	22	22	CD
555	3729	3736	Briefly	briefly	NNP
557	3738	3742	lung	lung	NN
558	3753	3759	tissue	tissue	NN
559	3760	3768	sections	section	NNS
560	3769	3773	were	be	VBD
561	3774	3780	finely	finely	RB
562	3781	3784	cut	cut	VB
563	3785	3789	with	with	IN
564	3790	3797	sterile	sterile	JJ
565	3798	3806	scissors	scissors	NNS
566	3807	3810	and	and	CC
567	3821	3830	incubated	incubated	JJ
568	3831	3835	with	with	IN
569	3836	3841	serum	serum	NN
570	3842	3846	free	free	JJ
571	3847	3851	DMEM	dmem	NNP
572	3852	3862	containing	contain	VBG
573	3863	3870	trypsin	trypsin	NN
575	3872	3877	DNAse	dnase	NNP
576	3888	3891	and	and	CC
577	3892	3903	collagenase	collagenase	NN
578	3904	3907	for	for	IN
579	3908	3910	30	30	CD
580	3911	3915	min.	min.	NN
581	3916	3919	The	the	DT
582	3920	3929	procedure	procedure	NN
583	3930	3933	was	be	VBD
584	3934	3942	repeated	repeat	VBN
585	3953	3958	twice	twice	RB
587	3960	3963	and	and	CC
588	3964	3967	the	the	DT
589	3968	3980	supernatants	supernatant	NNS
590	3981	3985	were	be	VBD
591	3986	3992	pooled	pool	VBN
592	3993	3996	and	and	CC
593	3997	4005	cultured	cultured	JJ
594	4006	4008	in	in	IN
595	4019	4022	one	one	CD
596	4023	4026	100	100	CD
597	4027	4029	mm	mm	NN
598	4030	4035	plate	plate	NN
599	4036	4039	and	and	CC
600	4040	4049	incubated	incubated	JJ
601	4050	4052	at	at	IN
602	4053	4055	37	37	CD
605	4058	4060	in	in	IN
606	4061	4062	a	a	DT
607	4063	4064	5	5	CD
609	4066	4068	CO	co	NNP
610	4080	4081	2	2	CD
611	4082	4092	humidified	humidified	JJ
612	4093	4103	atmosphere	atmosphere	NN
614	4105	4112	Culture	culture	NNP
615	4123	4129	medium	medium	NN
617	4131	4135	DMEM	dmem	NNP
618	4136	4140	with	with	IN
619	4141	4142	5	5	CD
621	4144	4149	fetal	fetal	JJ
622	4150	4156	bovine	bovine	JJ
623	4157	4162	serum	serum	NN
625	4164	4167	FBS	fbs	NNP
627	4169	4172	and	and	CC
628	4183	4193	penicillin	penicillin	NN
630	4194	4206	streptomycin	streptomycin	NN
632	4208	4211	was	be	VBD
633	4212	4220	replaced	replace	VBN
634	4221	4226	three	three	CD
635	4227	4232	times	time	NNS
636	4233	4236	per	per	IN
637	4247	4251	week	week	NN
638	4252	4255	and	and	CC
639	4256	4267	fibroblasts	fibroblast	NNS
640	4268	4272	were	be	VBD
641	4273	4279	passed	pass	VBN
643	4281	4282	1	1	CD
645	4283	4284	2	2	CD
646	4285	4290	split	split	NN
648	4292	4294	at	at	IN
649	4295	4298	the	the	DT
650	4299	4303	time	time	NN
651	4314	4318	they	they	PRP
652	4319	4325	became	become	VBD
653	4326	4335	confluent	confluent	NN
655	4337	4339	On	on	IN
656	4340	4347	passage	passage	NN
657	4348	4349	4	4	CD
658	4350	4353	the	the	DT
659	4354	4359	cells	cell	NNS
660	4360	4364	were	be	VBD
661	4375	4386	resuspended	resuspended	JJ
662	4387	4389	in	in	IN
663	4390	4391	1	1	CD
664	4392	4394	ml	ml	NN
665	4395	4397	of	of	IN
666	4398	4402	DMEM	dmem	NNP
667	4403	4407	with	with	IN
668	4408	4410	20	20	CD
670	4412	4415	FBS	fbs	NNP
671	4416	4419	and	and	CC
672	4420	4424	DMSO	dmso	NNP
673	4425	4428	and	and	CC
674	4439	4445	frozen	freeze	VBN
675	4446	4448	at	at	IN
677	4450	4452	70	70	CD
679	4453	4455	C.	C.	NN
680	4456	4459	For	for	IN
681	4460	4464	each	each	DT
682	4465	4475	experiment	experiment	NN
683	4476	4485	described	describe	VBD
684	4486	4491	below	below	IN
685	4492	4495	the	the	DT
686	4506	4511	cells	cell	NNS
687	4512	4516	were	be	VBD
688	4517	4523	thawed	thawed	JJ
690	4525	4533	cultured	cultured	JJ
691	4534	4537	and	and	CC
692	4538	4544	passed	pass	VBN
693	4545	4547	at	at	IN
694	4548	4553	least	least	JJS
695	4554	4558	once	once	RB
697	4560	4563	All	all	DT
698	4574	4577	the	the	DT
699	4578	4589	experiments	experiment	NNS
700	4590	4594	were	be	VBD
701	4595	4604	conducted	conduct	VBN
702	4605	4609	with	with	IN
703	4610	4615	cells	cell	NNS
704	4616	4618	at	at	IN
705	4619	4627	passages	passage	NNS
706	4628	4629	6	6	CD
707	4640	4642	to	to	TO
708	4643	4644	8	8	CD
710	4674	4683	Inducible	inducible	NNP
711	4684	4698	cyclooxygenase	cyclooxygenase	NN
712	4699	4706	(COX)-2	(cox)-2	NNP
713	4707	4717	expression	expression	NN
714	4718	4721	and	and	CC
715	4732	4742	eicosanoid	eicosanoid	NN
716	4743	4753	production	production	NN
717	4764	4769	COX-2	cox-2	NNP
718	4770	4778	activity	activity	NN
719	4779	4782	was	be	VBD
720	4783	4793	determined	determine	VBN
721	4794	4796	by	by	IN
722	4797	4806	measuring	measure	VBG
723	4807	4810	PGE	pge	NNP
724	4822	4823	2	2	CD
726	4826	4836	6-keto-PGF	6-keto-PGF	NN
727	4848	4849	1	1	CD
730	4852	4858	stable	stable	JJ
731	4859	4862	PGI	pgi	NNP
732	4874	4875	2	2	CD
733	4876	4886	metabolite	metabolite	NN
736	4889	4892	TXB	txb	NNP
737	4904	4905	2	2	CD
739	4907	4913	stable	stable	JJ
740	4914	4917	TXA	txa	NNP
741	4929	4930	2	2	CD
742	4931	4941	metabolite	metabolite	NN
745	4944	4947	and	and	CC
746	4948	4951	PGF	pgf	NNP
747	4963	4964	2	2	CD
749	4966	4976	production	production	NN
750	4977	4979	in	in	IN
751	4980	4990	stimulated	stimulate	VBN
752	5001	5012	fibroblasts	fibroblast	NNS
754	5014	5020	HF-IPF	hf-ipf	NNP
758	5026	5027	7	7	CD
760	5029	5032	and	and	CC
761	5033	5038	HF-NL	hf-nl	NNP
765	5044	5045	5	5	CD
767	5047	5051	were	be	VBD
768	5062	5069	brought	bring	VBN
769	5070	5072	to	to	TO
771	5074	5076	90	90	CD
773	5078	5088	confluency	confluency	NN
774	5089	5091	in	in	IN
775	5092	5095	100	100	CD
776	5095	5097	mm	mm	NN
777	5098	5104	plates	plate	NNS
778	5105	5108	and	and	CC
779	5109	5113	then	then	RB
780	5124	5130	placed	place	VBN
781	5131	5133	on	on	IN
782	5134	5139	serum	serum	NN
783	5140	5144	free	free	JJ
784	5145	5149	DMEM	dmem	NNP
785	5150	5153	for	for	IN
786	5154	5156	24	24	CD
787	5157	5162	hours	hour	NNS
788	5163	5165	to	to	TO
789	5166	5172	render	render	VB
790	5173	5177	them	them	PRP
791	5188	5197	quiescent	quiescent	JJ
793	5199	5210	Fibroblasts	fibroblasts	NNP
794	5211	5215	were	be	VBD
795	5216	5220	then	then	RB
796	5221	5230	incubated	incubated	JJ
797	5231	5233	in	in	IN
798	5234	5238	DMEM	dmem	NNP
799	5239	5243	with	with	IN
800	5254	5255	5	5	CD
802	5257	5260	FBS	fbs	NNP
803	5261	5266	alone	alone	RB
804	5267	5269	or	or	CC
805	5270	5272	in	in	IN
806	5273	5276	the	the	DT
807	5277	5281	same	same	JJ
808	5282	5288	medium	medium	NN
809	5289	5293	with	with	IN
810	5294	5299	IL-1?	il-1?	NNP
812	5301	5304	2.5	2.5	CD
813	5305	5307	ng	ng	NN
815	5308	5310	ml	ml	NN
817	5322	5325	for	for	IN
818	5326	5328	24	24	CD
819	5329	5334	hours	hour	NNS
821	5336	5338	At	at	IN
822	5339	5342	the	the	DT
823	5343	5346	end	end	NN
824	5347	5349	of	of	IN
825	5350	5353	the	the	DT
826	5354	5364	incubation	incubation	NN
827	5365	5371	period	period	NN
828	5372	5375	the	the	DT
829	5386	5397	supernatant	supernatant	NN
830	5398	5401	was	be	VBD
831	5402	5411	aspirated	aspirated	JJ
832	5412	5415	and	and	CC
833	5416	5421	fresh	fresh	JJ
834	5422	5427	media	media	NNS
835	5428	5438	containing	contain	VBG
836	5439	5441	30	30	CD
837	5452	5454	?M	?m	NN
838	5455	5457	of	of	IN
839	5458	5469	arachidonic	arachidonic	JJ
840	5470	5474	acid	acid	NN
841	5475	5478	was	be	VBD
842	5479	5484	added	add	VBN
843	5485	5487	to	to	TO
844	5488	5491	the	the	DT
845	5492	5498	plates	plate	NNS
847	5500	5505	After	after	IN
848	5506	5508	30	30	CD
849	5519	5522	min	min	NN
850	5523	5525	of	of	IN
851	5526	5536	incubation	incubation	NN
852	5537	5540	the	the	DT
853	5541	5552	supernatant	supernatant	NN
854	5553	5556	was	be	VBD
855	5557	5566	collected	collect	VBN
856	5567	5570	and	and	CC
857	5571	5576	saved	save	VBN
858	5587	5589	at	at	IN
860	5591	5593	70	70	CD
863	5596	5599	for	for	IN
864	5600	5605	later	later	RB
865	5606	5616	eicosanoid	eicosanoid	NN
866	5617	5625	analysis	analysis	NN
868	5627	5630	The	the	DT
869	5631	5636	cells	cell	NNS
870	5637	5641	were	be	VBD
871	5652	5656	then	then	RB
872	5657	5668	resuspended	resuspended	JJ
873	5669	5672	and	and	CC
874	5673	5680	divided	divide	VBN
875	5681	5685	into	into	IN
876	5686	5689	two	two	CD
877	5690	5698	aliquots	aliquot	NNS
879	5700	5705	which	which	WDT
880	5716	5720	were	be	VBD
881	5721	5725	used	use	VBN
882	5726	5729	for	for	IN
883	5730	5733	RNA	rna	NNP
884	5734	5737	and	and	CC
885	5738	5745	protein	protein	NN
886	5746	5757	extractions	extraction	NNS
888	5759	5771	respectively	respectively	RB
890	5783	5786	The	the	DT
891	5787	5792	above	above	IN
892	5793	5804	experiments	experiment	NNS
893	5805	5809	were	be	VBD
894	5810	5818	repeated	repeat	VBN
895	5819	5821	in	in	IN
896	5822	5828	HF-IPF	hf-ipf	NNP
900	5834	5835	2	2	CD
902	5837	5840	and	and	CC
903	5851	5856	HF-NL	hf-nl	NNP
907	5862	5863	2	2	CD
909	5865	5870	using	use	VBG
910	5871	5876	serum	serum	NN
911	5877	5881	free	free	JJ
912	5882	5887	media	media	NNS
913	5888	5898	conditions	condition	NNS
915	5910	5921	Prostanoids	prostanoids	NNP
916	5922	5926	were	be	VBD
917	5927	5935	measured	measure	VBN
918	5936	5938	by	by	IN
919	5939	5947	modified	modify	VBN
920	5948	5954	stable	stable	JJ
921	5955	5962	isotope	isotope	NN
922	5973	5981	dilution	dilution	NN
923	5982	5988	assays	assay	NNS
924	5989	5993	that	that	WDT
925	5994	5998	used	use	VBD
926	5999	6002	gas	gas	NN
927	6003	6017	chromatography	chromatography	NN
929	6018	6026	negative	negative	JJ
930	6037	6040	ion	ion	NN
932	6041	6049	chemical	chemical	JJ
933	6050	6060	ionization	ionization	NN
934	6061	6065	mass	mass	NN
935	6066	6078	spectrometry	spectrometry	NN
936	6079	6081	as	as	RB
937	6082	6092	previously	previously	RB
938	6103	6112	described	describe	VBD
940	6115	6117	23	23	CD
943	6122	6129	Briefly	briefly	NNP
945	6131	6140	deuterium	deuterium	NN
947	6141	6148	labeled	label	JJ
948	6149	6157	internal	internal	JJ
949	6168	6177	standards	standard	NNS
950	6178	6180	of	of	IN
951	6181	6184	PGE	pge	NNP
952	6196	6197	2	2	CD
954	6200	6203	PGF	pgf	NNP
955	6215	6216	2	2	CD
958	6220	6223	TXB	txb	NNP
959	6235	6236	2	2	CD
961	6239	6242	and	and	CC
962	6243	6253	6-keto-PGF	6-keto-PGF	NN
963	6265	6266	1	1	CD
965	6268	6272	were	be	VBD
966	6273	6278	added	add	VBN
967	6279	6281	to	to	TO
968	6282	6285	the	the	DT
969	6286	6298	supernatants	supernatant	NNS
970	6299	6303	with	with	IN
971	6314	6323	isopropyl	isopropyl	NN
972	6324	6331	alcohol	alcohol	NN
974	6333	6342	Isopropyl	isopropyl	NNP
975	6343	6350	alcohol	alcohol	NN
976	6351	6354	was	be	VBD
977	6355	6362	removed	remove	VBN
978	6363	6365	by	by	IN
979	6376	6387	evaporation	evaporation	NN
980	6388	6393	under	under	IN
981	6394	6402	nitrogen	nitrogen	NN
983	6404	6409	After	after	IN
984	6410	6423	acidification	acidification	NN
985	6424	6426	to	to	TO
986	6427	6429	pH	ph	NN
987	6440	6443	3.5	3.5	CD
989	6445	6448	the	the	DT
990	6449	6456	samples	sample	NNS
991	6457	6461	were	be	VBD
992	6462	6471	extracted	extract	VBN
993	6472	6474	on	on	IN
994	6475	6489	preconditioned	preconditioned	JJ
995	6490	6494	C-18	c-18	NNP
996	6505	6512	PrepSep	prepsep	NNP
997	6513	6520	columns	column	NNS
999	6522	6528	Fisher	fisher	NNP
1000	6529	6539	Scientific	scientific	NNP
1002	6541	6545	Fair	fair	NNP
1003	6546	6550	Lawn	lawn	NNP
1005	6552	6554	NJ	nj	NNP
1008	6557	6560	and	and	CC
1009	6571	6577	eluted	eluted	JJ
1010	6578	6582	with	with	IN
1011	6583	6588	ethyl	ethyl	NN
1012	6589	6596	acetate	acetate	NN
1014	6598	6601	The	the	DT
1015	6602	6609	extract	extract	NN
1016	6610	6613	was	be	VBD
1017	6614	6618	then	then	RB
1018	6619	6628	converted	convert	VBN
1019	6639	6641	to	to	TO
1020	6642	6643	a	a	DT
1021	6644	6661	pentafluorobenzyl	pentafluorobenzyl	NN
1022	6662	6667	ester	ester	NN
1023	6668	6670	by	by	IN
1024	6671	6680	treatment	treatment	NN
1025	6681	6685	with	with	IN
1026	6686	6687	a	a	DT
1027	6688	6695	mixture	mixture	NN
1028	6706	6708	of	of	IN
1029	6709	6713	12.5	12.5	CD
1031	6715	6732	pentafluorobenzyl	pentafluorobenzyl	NN
1032	6733	6740	bromide	bromide	NN
1033	6741	6743	in	in	IN
1034	6744	6756	acetonitrile	acetonitrile	NN
1035	6757	6760	and	and	CC
1036	6771	6791	disopropylethylamine	disopropylethylamine	NN
1037	6792	6794	at	at	IN
1038	6795	6799	room	room	NN
1039	6800	6811	temperature	temperature	NN
1040	6812	6815	for	for	IN
1041	6816	6818	30	30	CD
1042	6819	6823	min.	min.	NN
1043	6834	6839	After	after	IN
1044	6840	6851	evaporation	evaporation	NN
1045	6852	6854	of	of	IN
1046	6855	6863	reagents	reagent	NNS
1048	6865	6868	the	the	DT
1049	6869	6876	residue	residue	NN
1050	6877	6880	was	be	VBD
1051	6881	6890	subjected	subject	VBN
1052	6901	6903	to	to	TO
1053	6904	6907	TLC	tlc	NNP
1054	6908	6914	plates	plate	NNS
1056	6916	6921	using	use	VBG
1057	6922	6925	the	the	DT
1058	6926	6933	solvent	solvent	JJ
1059	6934	6940	system	system	NN
1060	6951	6961	chloroform	chloroform	NN
1062	6962	6969	ethanol	ethanol	NN
1064	6971	6973	93	93	CD
1066	6974	6975	7	7	CD
1068	6977	6980	vol	vol	NN
1070	6981	6984	vol	vol	NN
1072	6986	6989	for	for	IN
1073	6990	6993	PGF	pgf	NNP
1074	7005	7006	2	2	CD
1076	7008	7011	and	and	CC
1077	7012	7015	TXB	txb	NNP
1078	7027	7028	2	2	CD
1080	7031	7034	and	and	CC
1081	7035	7040	ethyl	ethyl	NN
1082	7041	7048	acetate	acetate	NN
1084	7049	7057	methanol	methanol	NN
1086	7059	7061	93	93	CD
1088	7062	7063	2	2	CD
1090	7075	7078	vol	vol	NN
1092	7079	7082	vol	vol	NN
1094	7084	7087	for	for	IN
1095	7088	7098	6-keto-PGF	6-keto-PGF	NN
1096	7110	7111	1	1	CD
1098	7113	7116	and	and	CC
1099	7117	7120	PGE	pge	NNP
1100	7132	7133	2	2	CD
1102	7136	7140	Then	then	RB
1103	7141	7144	PGF	pgf	NNP
1104	7156	7157	2	2	CD
1106	7159	7162	was	be	VBD
1107	7163	7172	converted	convert	VBN
1108	7173	7175	to	to	TO
1109	7176	7190	trimethylsilyl	trimethylsilyl	NN
1110	7201	7206	ether	ether	NN
1111	7207	7217	derivative	derivative	JJ
1112	7218	7220	by	by	IN
1113	7221	7230	treatment	treatment	NN
1114	7231	7235	with	with	IN
1115	7236	7243	N,O-bis	n,o-bis	NNP
1117	7255	7269	trimethylsilyl	trimethylsilyl	NN
1119	7271	7289	trifluoroacetamide	trifluoroacetamide	NN
1120	7290	7293	and	and	CC
1121	7304	7321	dimethylformamide	dimethylformamide	NN
1123	7323	7326	The	the	DT
1124	7327	7336	methoxime	methoxime	NN
1125	7337	7347	derivative	derivative	NN
1126	7348	7350	of	of	IN
1127	7351	7354	TXB	txb	NNP
1128	7366	7367	2	2	CD
1130	7370	7373	PGE	pge	NNP
1131	7385	7386	2	2	CD
1132	7387	7390	and	and	CC
1133	7391	7401	6-keto-PGF	6-keto-PGF	NN
1134	7413	7414	1	1	CD
1136	7416	7419	was	be	VBD
1137	7420	7424	made	make	VBN
1138	7425	7427	by	by	IN
1139	7428	7437	treatment	treatment	NN
1140	7438	7442	with	with	IN
1141	7443	7444	2	2	CD
1143	7456	7467	methoxamine	methoxamine	NN
1144	7468	7481	hydrochloride	hydrochloride	NN
1145	7482	7484	in	in	IN
1146	7485	7493	pyridine	pyridine	NN
1147	7494	7496	at	at	IN
1148	7497	7499	70	70	CD
1151	7502	7505	for	for	IN
1152	7506	7508	60	60	CD
1153	7509	7512	min	min	NN
1155	7524	7532	followed	follow	VBN
1156	7533	7535	by	by	IN
1157	7536	7547	evaporation	evaporation	NN
1158	7548	7550	of	of	IN
1159	7551	7554	the	the	DT
1160	7555	7563	pyridine	pyridine	NN
1162	7565	7573	addition	addition	NN
1163	7574	7576	of	of	IN
1164	7587	7592	water	water	NN
1166	7594	7597	and	and	CC
1167	7598	7608	extraction	extraction	NN
1168	7609	7613	with	with	IN
1169	7614	7619	ethyl	ethyl	NN
1170	7620	7627	acetate	acetate	NN
1172	7629	7643	Derivatization	derivatization	NNP
1173	7654	7657	was	be	VBD
1174	7658	7667	completed	complete	VBN
1175	7668	7670	by	by	IN
1176	7671	7680	formation	formation	NN
1177	7681	7683	of	of	IN
1178	7684	7687	the	the	DT
1179	7688	7702	trimethylsilyl	trimethylsilyl	NN
1180	7713	7724	derivatives	derivative	NNS
1181	7725	7727	by	by	IN
1182	7728	7737	treatment	treatment	NN
1183	7738	7742	with	with	IN
1184	7743	7750	N,O-bis	n,o-bis	NNP
1186	7752	7766	trimethylsilyl	trimethylsilyl	NN
1188	7778	7796	trifluoroacetamide	trifluoroacetamide	NN
1189	7797	7800	and	and	CC
1190	7801	7809	pyridine	pyridine	NN
1192	7811	7822	Eicosanoids	eicosanoids	NNP
1193	7823	7827	were	be	VBD
1194	7838	7848	quantified	quantify	VBN
1195	7849	7851	by	by	IN
1196	7852	7861	measuring	measure	VBG
1197	7862	7865	the	the	DT
1198	7866	7871	ratio	ratio	NN
1199	7872	7874	of	of	IN
1200	7875	7878	the	the	DT
1201	7879	7888	intensity	intensity	NN
1202	7889	7891	of	of	IN
1203	7902	7906	ions	ion	NNS
1207	7911	7918	569/573	569/573	CD
1208	7919	7922	for	for	IN
1209	7923	7926	PGF	pgf	NNP
1210	7938	7939	2	2	CD
1216	7947	7954	614/618	614/618	CD
1217	7955	7958	for	for	IN
1218	7959	7962	TXB	txb	NNP
1219	7974	7975	2	2	CD
1220	7976	7979	and	and	CC
1221	7980	7990	6-keto-PGF	6-keto-PGF	NN
1222	8002	8003	1	1	CD
1225	8007	8010	and	and	CC
1229	8015	8022	524/528	524/528	CD
1230	8023	8026	for	for	IN
1231	8027	8030	PGE	pge	NNP
1232	8042	8043	2	2	CD
1234	8046	8048	An	an	DT
1235	8049	8059	analytical	analytical	JJ
1236	8060	8065	blank	blank	NN
1237	8066	8069	for	for	IN
1238	8070	8074	each	each	DT
1239	8075	8077	of	of	IN
1240	8088	8093	these	these	DT
1241	8094	8102	products	product	NNS
1242	8103	8106	was	be	VBD
1243	8107	8117	determined	determine	VBN
1244	8118	8120	by	by	IN
1245	8121	8130	measuring	measure	VBG
1246	8131	8134	the	the	DT
1247	8135	8141	amount	amount	NN
1248	8142	8144	of	of	IN
1249	8155	8168	nondeuterated	nondeuterated	JJ
1250	8169	8177	material	material	NN
1252	8179	8187	detected	detect	VBD
1253	8188	8193	after	after	IN
1254	8194	8204	extracting	extract	VBG
1255	8205	8208	and	and	CC
1256	8219	8228	analyzing	analyze	VBG
1257	8229	8230	2	2	CD
1258	8231	8233	ml	ml	NN
1259	8234	8236	of	of	IN
1260	8237	8243	saline	saline	NN
1261	8244	8246	to	to	TO
1262	8247	8252	which	which	WDT
1263	8253	8256	the	the	DT
1264	8257	8274	deuterium-labeled	deuterium-labeled	JJ
1265	8285	8293	internal	internal	JJ
1266	8294	8303	standards	standard	NNS
1267	8304	8307	had	have	VBD
1268	8308	8312	been	be	VBN
1269	8313	8318	added	add	VBN
1271	8348	8355	Western	western	JJ
1272	8356	8364	analysis	analysis	NN
1273	8375	8380	After	after	IN
1274	8381	8388	washing	wash	VBG
1275	8389	8393	with	with	IN
1276	8394	8397	PBS	pbs	NNP
1277	8398	8400	at	at	IN
1278	8401	8403	pH	ph	NN
1279	8404	8407	7.4	7.4	CD
1281	8409	8416	pellets	pellet	NNS
1282	8417	8421	were	be	VBD
1283	8422	8427	lyzed	lyzed	JJ
1284	8438	8440	in	in	IN
1285	8441	8455	solubilization	solubilization	NN
1286	8456	8462	buffer	buffer	NN
1287	8463	8473	containing	contain	VBG
1288	8474	8476	50	50	CD
1289	8477	8479	mM	mm	NN
1290	8480	8484	TRIS	tris	NNP
1291	8485	8487	at	at	IN
1292	8488	8490	pH	ph	NN
1293	8491	8492	8	8	CD
1295	8504	8505	1	1	CD
1297	8507	8512	Tween	tween	NNP
1298	8513	8515	20	20	CD
1300	8517	8519	10	10	CD
1301	8520	8522	mM	mm	NN
1302	8523	8544	phenylmethylsulphonyl	phenylmethylsulphonyl	NN
1303	8545	8553	fluoride	fluoride	NN
1305	8565	8586	diethyldithiocarbamic	diethyldithiocarbamic	JJ
1306	8587	8591	acid	acid	NN
1308	8593	8602	leupeptin	leupeptin	NN
1309	8603	8606	and	and	CC
1310	8607	8616	pepstatin	pepstatin	NN
1313	8630	8633	all	all	DT
1314	8634	8638	from	from	IN
1315	8639	8644	Sigma	sigma	NNP
1316	8645	8653	Chemical	chemical	NNP
1319	8656	8665	sonicated	sonicated	JJ
1321	8667	8673	boiled	boil	VBD
1322	8674	8678	with	with	IN
1323	8679	8682	gel	gel	NN
1324	8693	8700	loading	loading	NN
1325	8701	8707	buffer	buffer	NN
1327	8709	8713	62.5	62.5	CD
1328	8714	8716	mM	mm	NN
1329	8717	8725	TRIS-HCl	tris-hcl	NNP
1331	8727	8729	at	at	IN
1332	8730	8732	pH	ph	NN
1333	8733	8736	6.8	6.8	CD
1335	8738	8740	10	10	CD
1337	8752	8760	glycerol	glycerol	NN
1339	8762	8763	2	2	CD
1341	8765	8768	SDS	sds	NNP
1343	8770	8771	5	5	CD
1345	8773	8790	?-mercaptoethanol	?-mercaptoethanol	JJ
1347	8792	8795	and	and	CC
1348	8796	8807	bromophenol	bromophenol	NN
1349	8818	8822	blue	blue	JJ
1352	8825	8828	and	and	CC
1353	8829	8840	centrifuged	centrifuged	JJ
1354	8841	8843	at	at	IN
1355	8844	8850	15,000	15,000	CD
1358	8866	8869	for	for	IN
1359	8870	8872	10	10	CD
1360	8873	8877	min.	min.	NN
1361	8878	8883	Equal	equal	NNP
1362	8884	8891	amounts	amount	NNS
1363	8892	8894	of	of	IN
1364	8905	8912	protein	protein	NN
1366	8914	8916	70	70	CD
1367	8917	8919	to	to	TO
1368	8920	8923	100	100	CD
1369	8924	8926	?g	?g	NN
1371	8928	8932	were	be	VBD
1372	8933	8942	separated	separate	VBN
1373	8943	8945	by	by	IN
1374	8946	8961	electrophoresis	electrophoresis	NNS
1376	8973	8981	SDS-PAGE	sds-page	NNP
1377	8982	8985	was	be	VBD
1378	8986	8995	performed	perform	VBN
1379	8996	9001	using	use	VBG
1380	9002	9003	a	a	DT
1381	9004	9007	7.5	7.5	CD
1383	9009	9019	separating	separate	VBG
1384	9020	9023	gel	gel	NN
1385	9024	9028	with	with	IN
1386	9029	9030	a	a	DT
1387	9041	9042	4	4	CD
1389	9044	9052	stacking	stack	VBG
1390	9053	9056	gel	gel	NN
1392	9058	9061	The	the	DT
1393	9062	9070	resolved	resolve	VBN
1394	9071	9079	proteins	protein	NNS
1395	9080	9084	were	be	VBD
1396	9085	9096	transferred	transfer	VBN
1397	9107	9126	electrophoretically	electrophoretically	RB
1398	9127	9129	to	to	TO
1399	9130	9144	nitrocellulose	nitrocellulose	NN
1400	9145	9154	membranes	membrane	NNS
1402	9166	9173	Hybond-	hybond-	NNP
1403	9173	9176	ECL	ecl	NNP
1405	9178	9186	Amersham	amersham	NNP
1406	9187	9191	Corp	corp	NNP
1410	9195	9200	After	after	IN
1411	9201	9209	transfer	transfer	NN
1413	9211	9214	the	the	DT
1414	9215	9222	filters	filter	NNS
1415	9233	9237	were	be	VBD
1416	9238	9247	incubated	incubated	JJ
1417	9248	9257	overnight	overnight	JJ
1418	9258	9260	at	at	IN
1419	9261	9262	4	4	CD
1422	9265	9267	in	in	IN
1423	9268	9269	a	a	DT
1424	9270	9278	blocking	block	VBG
1425	9279	9287	solution	solution	NN
1427	9299	9301	20	20	CD
1428	9302	9304	mM	mm	NN
1429	9305	9309	TRIS	tris	NNP
1430	9310	9314	base	base	NN
1432	9316	9319	137	137	CD
1433	9320	9322	mM	mm	NN
1434	9323	9329	sodium	sodium	NN
1435	9330	9338	chloride	chloride	NN
1436	9339	9341	at	at	IN
1437	9342	9344	pH	ph	NN
1438	9345	9348	7.6	7.6	CD
1440	9350	9351	5	5	CD
1442	9363	9371	powdered	powdered	JJ
1443	9372	9376	milk	milk	NN
1445	9378	9379	3	3	CD
1447	9381	9384	BSA	bsa	NNP
1450	9387	9390	and	and	CC
1451	9391	9400	incubated	incubated	JJ
1452	9401	9405	with	with	IN
1453	9406	9413	primary	primary	JJ
1454	9424	9434	polyclonal	polyclonal	NN
1455	9435	9441	rabbit	rabbit	NN
1456	9442	9452	antibodies	antibody	NNS
1457	9453	9460	against	against	IN
1458	9461	9466	COX-2	cox-2	NNP
1459	9467	9469	at	at	IN
1460	9470	9471	a	a	DT
1461	9472	9480	dilution	dilution	NN
1462	9491	9492	1	1	CD
1464	9493	9497	1000	1000	CD
1466	9499	9505	Cayman	cayman	NNP
1467	9506	9514	Chemical	chemical	NNP
1469	9516	9519	Ann	ann	NNP
1470	9520	9525	Arbor	arbor	NNP
1472	9527	9529	MI	mi	NNP
1475	9532	9535	for	for	IN
1476	9536	9537	1	1	CD
1477	9538	9542	hour	hour	NN
1478	9543	9545	at	at	IN
1479	9556	9560	room	room	NN
1480	9561	9572	temperature	temperature	NN
1482	9574	9577	The	the	DT
1483	9578	9585	filters	filter	NNS
1484	9586	9590	were	be	VBD
1485	9591	9597	washed	wash	VBN
1487	9599	9602	TBS	tbs	NNP
1489	9603	9606	0.1	0.1	CD
1491	9608	9613	Tween	tween	NNP
1492	9624	9626	20	20	CD
1493	9627	9629	at	at	IN
1494	9630	9632	pH	ph	NN
1495	9633	9636	7.6	7.6	CD
1497	9638	9641	and	and	CC
1498	9642	9651	incubated	incubated	JJ
1499	9652	9656	with	with	IN
1500	9657	9668	horseradish	horseradish	NN
1501	9669	9679	peroxidase	peroxidase	NN
1502	9690	9696	linked	link	VBD
1503	9697	9706	secondary	secondary	JJ
1504	9707	9717	antibodies	antibody	NNS
1505	9718	9720	at	at	IN
1506	9721	9722	a	a	DT
1507	9723	9731	dilution	dilution	NN
1508	9732	9733	1	1	CD
1510	9734	9738	4000	4000	CD
1512	9750	9758	Amersham	amersham	NNP
1515	9761	9766	After	after	IN
1516	9767	9774	washing	wash	VBG
1518	9776	9779	the	the	DT
1519	9780	9789	membranes	membrane	NNS
1520	9790	9794	were	be	VBD
1521	9795	9804	incubated	incubated	JJ
1522	9815	9819	with	with	IN
1523	9820	9827	luminol	luminol	NN
1524	9828	9833	based	base	VBD
1525	9834	9851	chemiluminescence	chemiluminescence	NN
1526	9852	9859	reagent	reagent	NN
1528	9861	9867	DuPont	dupont	NNP
1529	9868	9871	NEN	nen	NNP
1530	9882	9890	Research	research	NNP
1531	9891	9899	Products	products	NNPS
1533	9901	9907	Boston	boston	NNP
1535	9909	9911	MA	ma	NNP
1538	9942	9950	Northern	northern	JJ
1539	9951	9959	analysis	analysis	NN
1540	9970	9974	Cell	cell	NNP
1541	9975	9982	pellets	pellet	NNS
1542	9983	9987	were	be	VBD
1543	9988	9993	lyzed	lyzed	JJ
1544	9994	9997	and	and	CC
1545	9998	10001	RNA	rna	NNP
1546	10002	10011	extracted	extract	VBD
1547	10012	10017	using	use	VBG
1548	10018	10021	the	the	DT
1549	10032	10038	RNeasy	rneasy	NNP
1550	10039	10045	method	method	NN
1553	10048	10054	Qiagen	qiagen	NNP
1556	10057	10066	following	follow	VBG
1557	10067	10070	the	the	DT
1558	10071	10083	manufacturer	manufacturer	NN
1560	10096	10108	instructions	instruction	NNS
1562	10110	10113	RNA	rna	NNP
1563	10114	10117	was	be	VBD
1564	10118	10128	quantified	quantify	VBN
1565	10129	10131	by	by	IN
1566	10132	10143	determining	determine	VBG
1567	10144	10149	light	light	JJ
1568	10160	10170	absorbance	absorbance	NN
1569	10171	10173	at	at	IN
1570	10174	10177	260	260	CD
1571	10178	10180	nm	nm	NN
1572	10181	10184	and	and	CC
1573	10185	10189	then	then	RB
1574	10190	10200	fractioned	fractioned	JJ
1575	10201	10203	by	by	IN
1576	10214	10229	electrophoresis	electrophoresis	NNS
1578	10231	10233	10	10	CD
1579	10234	10236	?g	?g	NN
1580	10237	10240	per	per	IN
1581	10241	10245	lane	lane	NN
1583	10247	10249	on	on	IN
1584	10250	10251	a	a	DT
1585	10252	10253	1	1	CD
1587	10255	10262	agarose	agarose	NN
1588	10273	10277	MOPS	mops	NNP
1590	10278	10290	formaldehyde	formaldehyde	NN
1591	10291	10294	gel	gel	NN
1593	10296	10299	The	the	DT
1594	10300	10303	RNA	rna	NNP
1595	10304	10307	was	be	VBD
1596	10308	10317	denatured	denatured	JJ
1597	10318	10323	prior	prior	RB
1598	10324	10326	to	to	TO
1599	10337	10344	loading	loading	NN
1600	10345	10347	by	by	IN
1601	10348	10358	incubating	incubate	VBG
1602	10359	10362	the	the	DT
1603	10363	10366	RNA	rna	NNP
1604	10367	10369	at	at	IN
1605	10370	10372	65	65	CD
1608	10375	10378	for	for	IN
1609	10379	10381	10	10	CD
1610	10382	10385	min	min	NN
1611	10386	10388	in	in	IN
1612	10389	10390	a	a	DT
1613	10401	10408	loading	loading	NN
1614	10409	10415	buffer	buffer	NN
1615	10416	10426	comprising	comprise	VBG
1616	10427	10428	1	1	CD
1618	10430	10434	MOPS	mops	NNP
1620	10436	10438	50	50	CD
1622	10440	10449	formamide	formamide	NN
1624	10451	10454	6.5	6.5	CD
1626	10466	10478	formaldehyde	formaldehyde	NN
1628	10480	10481	5	5	CD
1630	10483	10491	glycerol	glycerol	NN
1632	10493	10496	0.1	0.1	CD
1633	10497	10499	mM	mm	NN
1634	10500	10504	EDTA	edta	NNP
1636	10506	10511	0.025	0.025	CD
1638	10523	10534	bromophenol	bromophenol	NN
1639	10535	10539	blue	blue	JJ
1641	10541	10546	0.025	0.025	CD
1643	10548	10554	xylene	xylene	NN
1644	10555	10561	cyanol	cyanol	NN
1646	10563	10566	The	the	DT
1647	10567	10570	RNA	rna	NNP
1648	10571	10574	was	be	VBD
1649	10585	10596	transferred	transfer	VBN
1650	10597	10599	by	by	IN
1651	10600	10607	gravity	gravity	NN
1653	10608	10616	assisted	assist	VBN
1654	10617	10626	capillary	capillary	JJ
1655	10627	10633	method	method	NN
1656	10634	10638	with	with	IN
1657	10639	10640	6	6	CD
1659	10652	10655	SSC	ssc	NNP
1660	10656	10658	to	to	TO
1661	10659	10664	nylon	nylon	NN
1662	10665	10678	hybridization	hybridization	NN
1663	10679	10687	membrane	membrane	NN
1665	10689	10692	and	and	CC
1666	10693	10697	then	then	RB
1667	10698	10703	fixed	fix	VBN
1668	10704	10706	to	to	TO
1669	10717	10720	the	the	DT
1670	10721	10729	membrane	membrane	NN
1671	10730	10732	by	by	IN
1672	10733	10735	UV	uv	NNP
1673	10736	10748	crosslinking	crosslink	VBG
1675	10750	10762	Stratalinker	stratalinker	NNP
1676	10763	10767	1200	1200	CD
1677	10768	10770	?j	?j	NN
1679	10771	10773	cm	cm	NN
1680	10784	10785	2	2	CD
1683	10788	10804	Prehybridization	prehybridization	NNP
1684	10805	10808	and	and	CC
1685	10809	10822	hybridization	hybridization	NN
1686	10823	10827	were	be	VBD
1687	10828	10837	performed	perform	VBN
1688	10838	10840	at	at	IN
1689	10851	10853	42	42	CD
1692	10856	10859	and	and	CC
1693	10860	10865	using	use	VBG
1694	10866	10871	Quick	quick	NNP
1695	10872	10875	Hyb	hyb	NNP
1698	10878	10888	Stratagene	stratagene	NNP
1700	10890	10892	as	as	IN
1701	10893	10906	hybridization	hybridization	NN
1702	10917	10925	solution	solution	NN
1704	10927	10930	The	the	DT
1705	10931	10936	COX-2	cox-2	NNP
1706	10937	10942	probe	probe	NN
1707	10943	10946	was	be	VBD
1708	10947	10953	random	random	JJ
1709	10954	10960	primed	prime	VBN
1710	10961	10970	following	follow	VBG
1711	10971	10974	the	the	DT
1712	10985	10995	directions	direction	NNS
1713	10996	10998	of	of	IN
1714	10999	11002	the	the	DT
1715	11003	11015	manufacturer	manufacturer	NN
1717	11017	11026	Megaprime	megaprime	NNP
1720	11040	11048	Amersham	amersham	NNP
1722	11049	11058	Pharmacia	pharmacia	NNP
1725	11061	11064	The	the	DT
1726	11065	11073	membrane	membrane	NN
1727	11074	11077	was	be	VBD
1728	11078	11082	then	then	RB
1729	11083	11089	washed	wash	VBN
1730	11090	11092	at	at	IN
1731	11093	11094	a	a	DT
1732	11105	11110	final	final	JJ
1733	11111	11121	stringency	stringency	NN
1734	11122	11124	of	of	IN
1735	11125	11128	0.2	0.2	CD
1737	11130	11133	SSC	ssc	NNP
1739	11135	11138	0.1	0.1	CD
1741	11140	11143	SDS	sds	NNP
1743	11145	11147	at	at	IN
1744	11148	11150	60	60	CD
1747	11153	11156	for	for	IN
1748	11157	11159	30	30	CD
1749	11170	11174	min.	min.	NN
1750	11175	11178	The	the	DT
1751	11179	11187	membrane	membrane	NN
1752	11188	11191	was	be	VBD
1753	11192	11199	wrapped	wrap	VBN
1754	11200	11202	in	in	IN
1755	11203	11210	plastic	plastic	NN
1756	11211	11215	wrap	wrap	NN
1757	11216	11219	and	and	CC
1758	11220	11227	exposed	expose	VBN
1759	11238	11240	to	to	TO
1760	11241	11246	Kodak	kodak	NNP
1761	11247	11249	XR	xr	NNP
1762	11250	11254	film	film	NN
1763	11255	11257	at	at	IN
1765	11259	11261	70	70	CD
1768	11264	11268	with	with	IN
1769	11269	11280	intensifier	intensifier	NN
1770	11281	11287	screen	screen	NN
1771	11298	11307	overnight	overnight	JJ
1773	11337	11348	Statistical	statistical	NNP
1774	11349	11356	methods	method	NNS
1775	11367	11370	All	all	DT
1776	11371	11378	results	result	NNS
1777	11379	11382	are	be	VBP
1778	11383	11392	presented	present	VBN
1779	11393	11395	as	as	IN
1780	11396	11403	medians	median	NNS
1781	11404	11408	with	with	IN
1782	11409	11414	their	their	PRP$
1783	11415	11420	range	range	NN
1785	11432	11443	Comparisons	comparisons	NNP
1786	11444	11451	between	between	IN
1787	11452	11458	HF-IPF	hf-ipf	NNP
1788	11459	11462	and	and	CC
1789	11463	11468	HF-NL	hf-nl	NNP
1790	11469	11473	were	be	VBD
1791	11474	11478	done	do	VBN
1792	11479	11484	using	use	VBG
1793	11485	11488	the	the	DT
1794	11499	11503	Mann	mann	NNP
1796	11504	11511	Whitney	whitney	NNP
1797	11512	11516	test	test	NN
1801	11533	11538	value	value	NN
1802	11539	11541	of	of	IN
1804	11543	11547	0.05	0.05	CD
1805	11548	11551	was	be	VBD
1806	11552	11562	considered	consider	VBN
1807	11573	11584	significant	significant	JJ
1809	11617	11624	Results	result	NNS
1810	11644	11652	Baseline	baseline	NNP
1811	11653	11656	and	and	CC
1812	11657	11667	stimulated	stimulate	VBN
1813	11668	11673	COX-2	cox-2	NNP
1814	11674	11682	activity	activity	NN
1815	11683	11685	in	in	IN
1816	11686	11692	HF-IPF	hf-ipf	NNP
1817	11703	11706	and	and	CC
1818	11707	11712	HF-NL	hf-nl	NNP
1819	11723	11735	Unstimulated	unstimulated	NNP
1820	11736	11746	eicosanoid	eicosanoid	NN
1821	11747	11757	production	production	NN
1822	11758	11761	was	be	VBD
1823	11762	11769	similar	similar	JJ
1824	11770	11772	in	in	IN
1825	11773	11777	both	both	DT
1826	11788	11794	HF-IPF	hf-ipf	NNP
1827	11795	11798	and	and	CC
1828	11799	11804	HF-NL	hf-nl	NNP
1830	11806	11810	Fig.	Fig.	NN
1831	11811	11812	1	1	CD
1833	11814	11817	a-d	a-d	JJ
1836	11820	11824	When	when	WRB
1837	11825	11836	fibroblasts	fibroblast	NNS
1838	11837	11841	were	be	VBD
1839	11852	11862	stimulated	stimulate	VBN
1840	11863	11867	with	with	IN
1841	11868	11873	IL-1?	il-1?	NNP
1842	11874	11879	there	there	EX
1843	11880	11883	was	be	VBD
1844	11884	11885	a	a	DT
1845	11886	11897	significant	significant	JJ
1846	11898	11901	and	and	CC
1847	11902	11909	similar	similar	JJ
1848	11920	11932	upregulation	upregulation	NN
1849	11933	11935	of	of	IN
1850	11936	11939	PGE	pge	NNP
1851	11951	11952	2	2	CD
1852	11953	11963	production	production	NN
1853	11964	11966	in	in	IN
1854	11967	11971	both	both	DT
1855	11972	11978	HF-IPF	hf-ipf	NNP
1856	11979	11982	and	and	CC
1857	11983	11988	HF-NL	hf-nl	NNP
1859	12000	12005	28.35	28.35	CD
1861	12007	12012	range	range	NN
1863	12014	12018	9.09	9.09	CD
1865	12019	12024	89.09	89.09	CD
1867	12026	12032	versus	versus	CC
1868	12033	12038	17.12	17.12	CD
1870	12040	12044	8.58	8.58	CD
1872	12045	12050	29.33	29.33	CD
1874	12062	12064	ng	ng	NN
1876	12065	12067	10	10	CD
1877	12068	12069	6	6	CD
1878	12069	12074	cells	cell	NNS
1880	12075	12077	30	30	CD
1881	12078	12081	min	min	NN
1883	12083	12095	respectively	respectively	RB
1887	12112	12116	0.25	0.25	CD
1890	12119	12123	Fig.	Fig.	NN
1891	12124	12125	1	1	CD
1892	12125	12126	a	a	DT
1896	12140	12156	IL-1?-stimulated	il-1?-stimulated	NNP
1897	12157	12167	production	production	NN
1898	12168	12170	of	of	IN
1899	12171	12174	TXB	txb	NNP
1900	12186	12187	2	2	CD
1902	12189	12195	stable	stable	JJ
1903	12196	12206	metabolite	metabolite	NN
1904	12207	12209	of	of	IN
1905	12210	12213	the	the	DT
1906	12214	12220	active	active	JJ
1907	12221	12224	TXA	txa	NNP
1908	12246	12247	2	2	CD
1911	12251	12254	PGF	pgf	NNP
1912	12266	12267	2	2	CD
1915	12271	12274	and	and	CC
1916	12275	12285	6-keto-PGF	6-keto-PGF	NN
1917	12297	12298	1	1	CD
1920	12301	12307	stable	stable	JJ
1921	12308	12318	metabolite	metabolite	NN
1922	12319	12321	of	of	IN
1923	12322	12325	PGI	pgi	NNP
1924	12337	12338	2	2	CD
1926	12341	12350	increased	increase	VBN
1927	12351	12359	modestly	modestly	RB
1928	12360	12362	in	in	IN
1929	12363	12368	every	every	DT
1930	12369	12373	case	case	NN
1932	12385	12391	except	except	IN
1933	12392	12395	TXB	txb	NNP
1934	12407	12408	2	2	CD
1935	12409	12419	production	production	NN
1936	12420	12422	by	by	IN
1937	12423	12428	HF-NL	hf-nl	NNP
1939	12430	12435	which	which	WDT
1940	12436	12445	decreased	decrease	VBD
1942	12457	12461	0.75	0.75	CD
1944	12463	12467	0.15	0.15	CD
1946	12468	12472	2.58	2.58	CD
1948	12474	12476	ng	ng	NN
1950	12477	12479	10	10	CD
1951	12480	12481	6	6	CD
1952	12481	12486	cells	cell	NNS
1954	12487	12489	30	30	CD
1955	12490	12493	min	min	NN
1956	12494	12496	at	at	IN
1957	12497	12505	baseline	baseline	NN
1958	12506	12512	versus	versus	CC
1959	12523	12527	0.61	0.61	CD
1961	12529	12533	0.21	0.21	CD
1963	12534	12538	1.64	1.64	CD
1965	12540	12542	ng	ng	NN
1967	12543	12545	10	10	CD
1968	12546	12547	6	6	CD
1969	12547	12552	cells	cell	NNS
1971	12553	12555	30	30	CD
1972	12556	12559	min	min	NN
1973	12560	12564	with	with	IN
1974	12565	12570	IL-1?	il-1?	NNP
1975	12581	12592	stimulation	stimulation	NN
1978	12595	12599	Fig.	Fig.	NN
1979	12600	12601	1	1	CD
1983	12605	12612	Results	result	NNS
1984	12613	12615	of	of	IN
1985	12616	12619	PGE	pge	NNP
1986	12631	12632	2	2	CD
1987	12633	12643	production	production	NN
1988	12644	12648	were	be	VBD
1989	12649	12656	similar	similar	JJ
1990	12657	12661	when	when	WRB
1991	12672	12683	experiments	experiment	NNS
1992	12684	12688	were	be	VBD
1993	12689	12698	conducted	conduct	VBN
1994	12699	12701	in	in	IN
1995	12702	12707	serum	serum	NN
1996	12708	12712	free	free	JJ
1997	12713	12718	media	media	NNS
1998	12719	12729	conditions	condition	NNS
2000	12741	12748	results	result	NNS
2001	12749	12752	not	not	RB
2002	12753	12758	shown	show	VBN
2005	12771	12776	IL-1?	il-1?	NNP
2006	12777	12787	stimulated	stimulate	VBN
2007	12788	12791	TXB	txb	NNP
2008	12803	12804	2	2	CD
2009	12805	12815	production	production	NN
2010	12816	12819	was	be	VBD
2011	12820	12833	significantly	significantly	RB
2012	12834	12841	greater	greater	JJR
2013	12852	12854	in	in	IN
2014	12855	12861	HF-IPF	hf-ipf	NNP
2016	12863	12867	1.92	1.92	CD
2018	12869	12873	1.27	1.27	CD
2020	12874	12878	2.57	2.57	CD
2022	12880	12882	ng	ng	NN
2024	12883	12885	10	10	CD
2025	12886	12887	6	6	CD
2026	12887	12892	cells	cell	NNS
2028	12893	12895	30	30	CD
2029	12896	12899	min	min	NN
2031	12901	12905	than	than	IN
2032	12906	12908	in	in	IN
2033	12919	12924	HF-NL	hf-nl	NNP
2035	12926	12930	0.61	0.61	CD
2037	12932	12936	0.21	0.21	CD
2039	12937	12941	1.64	1.64	CD
2041	12943	12945	ng	ng	NN
2043	12946	12948	10	10	CD
2044	12949	12950	6	6	CD
2045	12950	12955	cells	cell	NNS
2047	12956	12958	30	30	CD
2048	12959	12962	min	min	NN
2052	12979	12984	0.007	0.007	CD
2055	12987	12991	Fig.	Fig.	NN
2056	12992	12993	1	1	CD
2060	12997	13005	baseline	baseline	NN
2061	13006	13009	TXB	txb	NNP
2062	13021	13022	2	2	CD
2063	13023	13033	production	production	NN
2064	13034	13037	was	be	VBD
2065	13038	13041	not	not	RB
2066	13042	13055	significantly	significantly	RB
2067	13066	13075	different	different	JJ
2068	13076	13083	between	between	IN
2069	13084	13087	the	the	DT
2070	13088	13091	two	two	CD
2071	13092	13096	cell	cell	NN
2072	13097	13103	groups	group	NNS
2074	13105	13109	1.73	1.73	CD
2076	13111	13115	0.77	0.77	CD
2078	13116	13120	2.53	2.53	CD
2080	13132	13138	versus	versus	CC
2081	13139	13143	0.75	0.75	CD
2083	13145	13149	0.15	0.15	CD
2085	13150	13154	2.58	2.58	CD
2087	13156	13158	ng	ng	NN
2089	13159	13161	10	10	CD
2090	13162	13163	6	6	CD
2091	13163	13168	cells	cell	NNS
2093	13169	13171	30	30	CD
2094	13172	13175	min	min	NN
2096	13177	13179	in	in	IN
2097	13180	13186	HF-IPF	hf-ipf	NNP
2098	13197	13200	and	and	CC
2099	13201	13206	HF-NL	hf-nl	NNP
2101	13208	13220	respectively	respectively	RB
2105	13237	13241	0.17	0.17	CD
2107	13243	13247	Fig.	Fig.	NN
2108	13248	13249	1	1	CD
2113	13254	13261	Because	because	IN
2114	13262	13265	PGI	pgi	NNP
2115	13277	13278	2	2	CD
2116	13279	13282	and	and	CC
2117	13283	13286	TXA	txa	NNP
2118	13298	13299	2	2	CD
2119	13300	13304	have	have	VBP
2120	13305	13313	opposing	oppose	VBG
2121	13314	13321	effects	effect	NNS
2122	13333	13335	in	in	IN
2123	13336	13340	vivo	vivo	NN
2125	13343	13345	we	we	PRP
2126	13346	13356	calculated	calculate	VBD
2127	13357	13360	the	the	DT
2128	13361	13366	ratio	ratio	NN
2129	13377	13379	of	of	IN
2130	13380	13385	their	their	PRP$
2131	13386	13397	metabolites	metabolite	NNS
2133	13399	13409	6-keto-PGF	6-keto-PGF	NN
2134	13421	13422	1	1	CD
2137	13425	13428	TXB	txb	NNP
2138	13440	13441	2	2	CD
2140	13444	13447	and	and	CC
2141	13448	13453	found	find	VBD
2142	13454	13455	a	a	DT
2143	13456	13469	significantly	significantly	RB
2144	13470	13475	lower	lower	JJR
2145	13486	13491	ratio	ratio	NN
2146	13492	13494	in	in	IN
2147	13495	13501	HF-IPF	hf-ipf	NNP
2148	13502	13504	at	at	IN
2149	13505	13513	baseline	baseline	NN
2151	13515	13519	0.08	0.08	CD
2153	13521	13525	0.04	0.04	CD
2155	13526	13530	0.52	0.52	CD
2157	13532	13538	versus	versus	CC
2158	13539	13543	0.12	0.12	CD
2160	13555	13559	0.11	0.11	CD
2162	13560	13564	0.89	0.89	CD
2164	13566	13568	in	in	IN
2165	13569	13575	HF-IPF	hf-ipf	NNP
2166	13576	13579	and	and	CC
2167	13580	13585	HF-NL	hf-nl	NNP
2169	13587	13599	respectively	respectively	RB
2173	13616	13621	0.028	0.028	CD
2175	13623	13626	and	and	CC
2176	13627	13628	a	a	DT
2177	13629	13636	similar	similar	JJ
2178	13637	13642	trend	trend	NN
2179	13653	13658	under	under	IN
2180	13659	13669	stimulated	stimulate	VBN
2181	13670	13680	conditions	condition	NNS
2183	13682	13686	0.24	0.24	CD
2185	13688	13692	0.05	0.05	CD
2187	13693	13697	1.53	1.53	CD
2189	13699	13705	versus	versus	CC
2190	13706	13710	1.08	1.08	CD
2192	13722	13726	0.51	0.51	CD
2194	13727	13731	3.79	3.79	CD
2196	13733	13735	in	in	IN
2197	13736	13742	HF-IPF	hf-ipf	NNP
2198	13743	13746	and	and	CC
2199	13747	13752	HF-NL	hf-nl	NNP
2201	13754	13766	respectively	respectively	RB
2205	13783	13787	0.09	0.09	CD
2207	13789	13793	Fig.	Fig.	NN
2208	13794	13795	2	2	CD
2212	13827	13835	Baseline	baseline	NNP
2213	13836	13839	and	and	CC
2214	13840	13850	stimulated	stimulate	VBN
2215	13851	13856	COX-2	cox-2	NNP
2216	13857	13867	expression	expression	NN
2217	13878	13885	Western	western	JJ
2218	13886	13890	blot	blot	NN
2219	13891	13893	in	in	IN
2220	13894	13906	unstimulated	unstimulated	JJ
2221	13907	13918	fibroblasts	fibroblast	NNS
2222	13919	13925	showed	show	VBD
2223	13926	13928	no	no	DT
2224	13939	13949	detectable	detectable	JJ
2225	13950	13955	COX-2	cox-2	NNP
2226	13956	13963	protein	protein	NN
2227	13964	13966	in	in	IN
2228	13967	13973	either	either	DT
2229	13974	13979	group	group	NN
2230	13980	13982	of	of	IN
2231	13983	13988	cells	cell	NNS
2233	13990	13995	while	while	IN
2234	14006	14011	IL-1?	il-1?	NNP
2235	14012	14025	significantly	significantly	RB
2236	14026	14033	induced	induce	VBD
2237	14034	14039	COX-2	cox-2	NNP
2238	14040	14042	to	to	TO
2239	14043	14044	a	a	DT
2240	14045	14052	similar	similar	JJ
2241	14053	14059	degree	degree	NN
2242	14060	14062	in	in	IN
2243	14073	14076	IPF	ipf	NNP
2244	14077	14080	and	and	CC
2245	14081	14087	normal	normal	JJ
2246	14088	14092	lung	lung	NN
2247	14093	14104	fibroblasts	fibroblast	NNS
2249	14106	14110	Fig.	Fig.	NN
2250	14111	14112	3	3	CD
2253	14115	14123	Northern	northern	NNP
2254	14124	14128	blot	blot	NN
2255	14139	14145	showed	show	VBD
2256	14146	14153	minimal	minimal	JJ
2257	14154	14159	COX-2	cox-2	NNP
2258	14160	14164	mRNA	mrna	NN
2259	14165	14167	in	in	IN
2260	14168	14180	unstimulated	unstimulated	JJ
2261	14181	14186	cells	cell	NNS
2262	14187	14190	and	and	CC
2263	14201	14212	significant	significant	JJ
2264	14213	14225	upregulation	upregulation	NN
2265	14226	14228	of	of	IN
2266	14229	14234	COX-2	cox-2	NNP
2267	14235	14239	mRNA	mrna	NN
2268	14240	14250	expression	expression	NN
2269	14251	14255	when	when	WRB
2270	14266	14276	stimulated	stimulate	VBN
2271	14277	14281	with	with	IN
2272	14282	14287	IL-1?	il-1?	NNP
2273	14288	14290	in	in	IN
2274	14291	14295	both	both	DT
2275	14296	14302	HF-IPF	hf-ipf	NNP
2276	14303	14306	and	and	CC
2277	14307	14312	HF-NL	hf-nl	NNP
2279	14314	14318	Fig.	Fig.	NN
2280	14329	14330	4	4	CD
2283	14364	14374	Discussion	discussion	NNP
2284	14383	14390	Several	several	JJ
2285	14391	14398	factors	factor	NNS
2286	14399	14407	modulate	modulate	VBP
2287	14408	14418	fibroblast	fibroblast	NN
2288	14419	14432	proliferation	proliferation	NN
2289	14433	14436	and	and	CC
2290	14445	14453	collagen	collagen	NN
2291	14454	14464	production	production	NN
2293	14466	14475	including	include	VBG
2294	14476	14485	mitogenic	mitogenic	JJ
2295	14486	14495	cytokines	cytokine	NNS
2297	14497	14501	e.g.	e.g.	NN
2299	14511	14523	transforming	transform	VBG
2300	14524	14530	growth	growth	NN
2301	14531	14537	factor	factor	NN
2304	14541	14545	TGF?	tgf?	NNP
2307	14548	14556	platelet	platelet	NN
2309	14557	14564	derived	derive	VBN
2310	14573	14579	growth	growth	NN
2311	14580	14586	factor	factor	NN
2313	14588	14592	PDGF	pdgf	NNP
2316	14595	14600	basic	basic	JJ
2317	14601	14611	fibroblast	fibroblast	NN
2318	14612	14618	growth	growth	NN
2319	14619	14625	factor	factor	NN
2321	14635	14639	bFGF	bfgf	NN
2325	14643	14654	eicosanoids	eicosanoid	NNS
2327	14656	14660	i.e.	i.e.	NN
2329	14662	14665	PGE	pge	NNP
2330	14675	14676	2	2	CD
2332	14679	14682	TXB	txb	NNP
2333	14692	14693	2	2	CD
2335	14696	14699	and	and	CC
2336	14700	14703	PGI	pgi	NNP
2337	14713	14714	2	2	CD
2340	14718	14721	and	and	CC
2341	14722	14736	antifibrogenic	antifibrogenic	JJ
2342	14737	14746	cytokines	cytokine	NNS
2344	14748	14752	e.g.	e.g.	NN
2345	14761	14766	IFN-?	ifn-?	NNP
2348	14770	14771	1	1	CD
2349	14772	14773	2	2	CD
2350	14774	14775	3	3	CD
2353	14780	14782	It	it	PRP
2354	14783	14785	is	be	VBZ
2355	14786	14790	very	very	RB
2356	14791	14797	likely	likely	JJ
2357	14798	14802	that	that	IN
2358	14803	14804	a	a	DT
2359	14805	14812	complex	complex	JJ
2360	14821	14832	interaction	interaction	NN
2361	14833	14838	among	among	IN
2362	14839	14844	these	these	DT
2363	14845	14852	factors	factor	NNS
2364	14853	14859	exists	exist	VBZ
2365	14860	14862	in	in	IN
2366	14863	14866	the	the	DT
2367	14867	14873	tissue	tissue	NN
2368	14874	14880	repair	repair	NN
2369	14889	14896	process	process	NN
2371	14898	14901	and	and	CC
2372	14902	14904	it	it	PRP
2373	14905	14907	is	be	VBZ
2374	14908	14916	possible	possible	JJ
2375	14917	14921	that	that	IN
2376	14922	14932	pathologic	pathologic	JJ
2377	14933	14941	fibrosis	fibrosis	NNS
2379	14943	14945	as	as	IN
2380	14946	14948	in	in	IN
2381	14957	14960	IPF	ipf	NNP
2383	14962	14969	results	result	VBZ
2384	14970	14974	from	from	IN
2385	14975	14987	phenotypical	phenotypical	JJ
2386	14988	14999	alterations	alteration	NNS
2387	15000	15002	in	in	IN
2388	15003	15014	fibroblasts	fibroblast	NNS
2389	15023	15027	that	that	WDT
2390	15028	15034	affect	affect	VBP
2391	15035	15038	the	the	DT
2393	15040	15046	normal	normal	JJ
2395	15048	15059	interaction	interaction	NN
2396	15060	15062	of	of	IN
2397	15063	15068	these	these	DT
2398	15069	15076	factors	factor	NNS
2400	15086	15089	Our	our	PRP$
2401	15090	15097	results	result	NNS
2402	15098	15102	show	show	VBP
2403	15103	15107	that	that	DT
2404	15108	15119	stimulation	stimulation	NN
2405	15120	15122	of	of	IN
2406	15123	15130	primary	primary	JJ
2407	15131	15139	cultures	culture	NNS
2408	15140	15142	of	of	IN
2409	15151	15156	human	human	JJ
2410	15157	15161	lung	lung	NN
2411	15162	15173	fibroblasts	fibroblast	NNS
2412	15174	15178	with	with	IN
2413	15179	15182	the	the	DT
2414	15183	15191	proximal	proximal	NN
2415	15192	15200	cytokine	cytokine	NN
2416	15201	15206	IL-1?	il-1?	NNP
2417	15215	15226	upregulates	upregulate	NNS
2418	15227	15232	COX-2	cox-2	NNP
2419	15233	15240	protein	protein	NN
2420	15241	15244	and	and	CC
2421	15245	15249	mRNA	mrna	NN
2422	15250	15260	expression	expression	NN
2423	15261	15263	to	to	TO
2424	15264	15265	a	a	DT
2425	15266	15273	similar	similar	JJ
2426	15282	15288	degree	degree	NN
2427	15289	15291	in	in	IN
2428	15292	15298	normal	normal	JJ
2429	15299	15302	and	and	CC
2430	15303	15306	IPF	ipf	NNP
2431	15307	15318	fibroblasts	fibroblast	NNS
2433	15320	15323	TXA	txa	NNP
2434	15333	15334	2	2	CD
2435	15335	15345	production	production	NN
2436	15346	15352	tended	tend	VBD
2437	15353	15355	to	to	TO
2438	15356	15358	be	be	VB
2439	15359	15366	greater	greater	JJR
2440	15367	15369	in	in	IN
2441	15370	15373	IPF	ipf	NNP
2442	15382	15386	than	than	IN
2443	15387	15389	in	in	IN
2444	15390	15396	normal	normal	JJ
2445	15397	15408	fibroblasts	fibroblast	NNS
2446	15409	15411	at	at	IN
2447	15412	15420	baseline	baseline	NN
2449	15422	15426	when	when	WRB
2450	15427	15437	stimulated	stimulate	VBN
2451	15446	15450	with	with	IN
2452	15451	15456	IL-1?	il-1?	NNP
2453	15457	15461	this	this	DT
2454	15462	15472	difference	difference	NN
2455	15473	15479	became	become	VBD
2456	15480	15493	statistically	statistically	RB
2457	15502	15513	significant	significant	JJ
2459	15515	15518	The	the	DT
2460	15519	15524	ratio	ratio	NN
2461	15525	15527	of	of	IN
2462	15528	15531	PGI	pgi	NNP
2463	15541	15542	2	2	CD
2464	15543	15545	to	to	TO
2465	15546	15549	TXA	txa	NNP
2466	15559	15560	2	2	CD
2467	15561	15572	metabolites	metabolite	NNS
2468	15573	15576	was	be	VBD
2469	15577	15582	lower	lower	JJR
2470	15583	15585	in	in	IN
2471	15586	15589	IPF	ipf	NNP
2472	15598	15609	fibroblasts	fibroblast	NNS
2473	15610	15612	at	at	IN
2474	15613	15621	baseline	baseline	NN
2475	15622	15625	and	and	CC
2476	15626	15630	with	with	IN
2477	15631	15636	IL-1?	il-1?	NNP
2478	15637	15648	stimulation	stimulation	NN
2480	15650	15653	The	the	DT
2481	15662	15667	above	above	IN
2482	15668	15675	results	result	NNS
2483	15676	15683	suggest	suggest	VBP
2484	15684	15688	that	that	IN
2485	15689	15690	a	a	DT
2486	15691	15700	decreased	decrease	VBN
2487	15701	15704	PGI	pgi	NNP
2488	15714	15715	2	2	CD
2490	15717	15720	TXA	txa	NNP
2491	15730	15731	2	2	CD
2492	15732	15737	ratio	ratio	NN
2493	15738	15743	could	could	MD
2494	15744	15746	be	be	VB
2495	15747	15748	a	a	DT
2496	15749	15759	phenotypic	phenotypic	JJ
2497	15760	15770	alteration	alteration	NN
2498	15779	15786	present	present	JJ
2499	15787	15789	in	in	IN
2500	15790	15793	IPF	ipf	NNP
2501	15794	15805	fibroblasts	fibroblast	NNS
2503	15807	15816	resulting	result	VBG
2504	15817	15819	in	in	IN
2505	15820	15821	a	a	DT
2506	15822	15826	loss	loss	NN
2507	15827	15829	of	of	IN
2508	15830	15835	their	their	PRP$
2509	15844	15852	capacity	capacity	NN
2510	15853	15855	to	to	TO
2511	15856	15868	autoregulate	autoregulate	NN
2512	15869	15882	proliferation	proliferation	NN
2513	15883	15886	and	and	CC
2514	15887	15900	extracellular	extracellular	NN
2515	15909	15915	matrix	matrix	NN
2516	15916	15926	production	production	NN
2518	15936	15939	The	the	DT
2519	15940	15947	effects	effect	NNS
2520	15948	15950	of	of	IN
2521	15951	15954	PGs	pgs	NNP
2522	15955	15957	on	on	IN
2523	15958	15962	cell	cell	NN
2524	15963	15976	proliferation	proliferation	NN
2525	15977	15980	and	and	CC
2526	15981	15989	collagen	collagen	NN
2527	15998	16008	production	production	NN
2528	16009	16013	have	have	VBP
2529	16014	16018	been	be	VBN
2530	16019	16025	widely	widely	RB
2531	16026	16033	studied	study	VBN
2532	16034	16036	in	in	IN
2533	16037	16046	different	different	JJ
2534	16047	16051	cell	cell	NN
2535	16052	16057	types	type	NNS
2537	16068	16070	13	13	CD
2538	16071	16073	14	14	CD
2539	16074	16076	15	15	CD
2540	16077	16079	16	16	CD
2541	16080	16082	17	17	CD
2542	16083	16085	26	26	CD
2545	16090	16093	TXA	txa	NNP
2546	16103	16104	2	2	CD
2547	16105	16108	has	have	VBZ
2548	16109	16113	been	be	VBN
2549	16114	16121	studied	study	VBN
2550	16122	16133	extensively	extensively	RB
2551	16134	16141	because	because	IN
2552	16150	16152	of	of	IN
2553	16153	16156	its	its	PRP$
2554	16157	16165	apparent	apparent	JJ
2555	16166	16170	role	role	NN
2556	16171	16173	in	in	IN
2557	16174	16189	atherosclerosis	atherosclerosis	NNS
2559	16191	16194	due	due	JJ
2560	16195	16197	to	to	TO
2561	16198	16201	its	its	PRP$
2562	16210	16223	prothrombotic	prothrombotic	JJ
2563	16224	16227	and	and	CC
2564	16228	16237	mitogenic	mitogenic	JJ
2565	16238	16248	activities	activity	NNS
2566	16249	16251	on	on	IN
2567	16252	16260	vascular	vascular	NN
2568	16261	16267	smooth	smooth	JJ
2569	16276	16282	muscle	muscle	NN
2570	16283	16288	cells	cell	NNS
2572	16291	16293	15	15	CD
2573	16294	16296	16	16	CD
2576	16301	16306	These	these	DT
2577	16307	16316	mitogenic	mitogenic	JJ
2578	16317	16324	effects	effect	NNS
2579	16325	16328	are	be	VBP
2580	16337	16348	potentiated	potentiated	JJ
2581	16349	16351	by	by	IN
2582	16352	16358	growth	growth	NN
2583	16359	16366	factors	factor	NNS
2585	16369	16371	15	15	CD
2586	16372	16374	16	16	CD
2587	16375	16377	27	27	CD
2588	16378	16380	28	28	CD
2591	16385	16387	In	in	IN
2592	16388	16396	vascular	vascular	NN
2593	16405	16411	smooth	smooth	JJ
2594	16412	16418	muscle	muscle	NN
2595	16419	16424	cells	cell	NNS
2596	16425	16428	TXA	txa	NNP
2597	16438	16439	2	2	CD
2598	16440	16450	stimulates	stimulate	NNS
2599	16451	16460	synthesis	synthesis	NN
2600	16461	16463	of	of	IN
2601	16464	16468	bFGF	bfgf	NN
2602	16469	16472	and	and	CC
2603	16481	16490	increases	increase	VBZ
2604	16491	16494	the	the	DT
2605	16495	16505	expression	expression	NN
2606	16506	16508	of	of	IN
2607	16509	16512	the	the	DT
2608	16513	16518	proto	proto	JJ
2610	16519	16528	oncogenes	oncogene	NNS
2611	16538	16543	c-fos	c-fos	JJ
2613	16555	16560	c-myc	c-myc	JJ
2615	16563	16566	and	and	CC
2616	16576	16581	egr-1	egr-1	NN
2618	16584	16589	which	which	WDT
2619	16590	16593	are	be	VBP
2620	16594	16604	associated	associate	VBN
2621	16605	16609	with	with	IN
2622	16618	16623	entry	entry	NN
2623	16624	16628	into	into	IN
2624	16629	16632	the	the	DT
2625	16633	16637	cell	cell	NN
2626	16638	16644	growth	growth	NN
2627	16645	16650	cycle	cycle	NN
2629	16653	16655	15	15	CD
2632	16660	16662	In	in	IN
2633	16663	16671	addition	addition	NN
2635	16673	16676	TXA	txa	NNP
2636	16686	16687	2	2	CD
2637	16688	16697	increases	increase	NNS
2638	16698	16711	proliferation	proliferation	NN
2639	16712	16714	of	of	IN
2640	16715	16726	fibroblasts	fibroblast	NNS
2642	16737	16739	13	13	CD
2644	16742	16745	and	and	CC
2645	16746	16752	smooth	smooth	JJ
2646	16753	16759	muscle	muscle	NN
2648	16760	16764	like	like	IN
2649	16765	16775	glomerular	glomerular	NN
2650	16776	16785	mesangial	mesangial	NN
2651	16786	16791	cells	cell	NNS
2653	16802	16804	14	14	CD
2656	16817	16819	On	on	IN
2657	16820	16823	the	the	DT
2658	16824	16829	other	other	JJ
2659	16830	16834	hand	hand	NN
2661	16836	16839	PGI	pgi	NNP
2662	16849	16850	2	2	CD
2663	16851	16860	decreases	decrease	NNS
2664	16861	16869	vascular	vascular	NN
2665	16870	16876	smooth	smooth	JJ
2666	16877	16883	muscle	muscle	NN
2667	16884	16888	cell	cell	NN
2668	16897	16910	proliferation	proliferation	NN
2669	16911	16914	and	and	CC
2670	16915	16923	collagen	collagen	NN
2671	16924	16927	and	and	CC
2672	16928	16946	glycosaminoglycane	glycosaminoglycane	NN
2673	16955	16964	synthesis	synthesis	NN
2675	16966	16969	via	via	IN
2676	16970	16980	activation	activation	NN
2677	16981	16983	of	of	IN
2678	16984	16992	adenylyl	adenylyl	NN
2679	16993	17000	cyclase	cyclase	NN
2680	17001	17004	and	and	CC
2681	17013	17023	subsequent	subsequent	JJ
2682	17024	17034	production	production	NN
2683	17035	17037	of	of	IN
2684	17038	17042	cAMP	camp	NN
2686	17045	17047	17	17	CD
2689	17052	17061	Betaprost	betaprost	NNP
2691	17063	17065	an	an	DT
2692	17066	17072	analog	analog	NN
2693	17081	17083	of	of	IN
2694	17084	17087	PGI	pgi	NNP
2695	17097	17098	2	2	CD
2697	17101	17110	decreases	decrease	NNS
2698	17111	17122	procollagen	procollagen	NN
2699	17123	17124	I	i	PRP
2700	17125	17128	and	and	CC
2701	17129	17132	III	iii	NNP
2702	17133	17137	mRNA	mrna	NN
2703	17146	17156	expression	expression	NN
2704	17157	17159	in	in	IN
2705	17160	17167	cardiac	cardiac	JJ
2706	17168	17179	fibroblasts	fibroblast	NNS
2708	17182	17184	18	18	CD
2711	17189	17194	These	these	DT
2712	17195	17202	effects	effect	NNS
2713	17211	17214	may	may	MD
2714	17215	17225	counteract	counteract	VB
2715	17226	17229	the	the	DT
2716	17230	17241	profibrotic	profibrotic	JJ
2717	17242	17249	effects	effect	NNS
2718	17250	17254	seen	see	VBN
2719	17255	17259	with	with	IN
2720	17260	17263	TXA	txa	NNP
2721	17273	17274	2	2	CD
2722	17275	17278	and	and	CC
2723	17279	17281	it	it	PRP
2724	17282	17284	is	be	VBZ
2725	17285	17293	possible	possible	JJ
2726	17294	17298	that	that	IN
2727	17299	17301	an	an	DT
2728	17302	17312	alteration	alteration	NN
2729	17321	17323	of	of	IN
2730	17324	17325	a	a	DT
2732	17327	17333	normal	normal	JJ
2734	17335	17346	physiologic	physiologic	JJ
2735	17347	17354	balance	balance	NN
2736	17355	17362	between	between	IN
2737	17363	17366	PGI	pgi	NNP
2738	17376	17377	2	2	CD
2739	17378	17381	and	and	CC
2740	17382	17385	TXA	txa	NNP
2741	17395	17396	2	2	CD
2742	17397	17402	could	could	MD
2743	17403	17411	increase	increase	VB
2744	17412	17420	tendency	tendency	NN
2745	17421	17428	towards	towards	IN
2746	17437	17449	fibrogenesis	fibrogenesis	NNS
2748	17459	17461	It	it	PRP
2749	17462	17464	is	be	VBZ
2750	17465	17474	important	important	JJ
2751	17475	17477	to	to	TO
2752	17478	17485	mention	mention	VB
2753	17486	17490	that	that	IN
2754	17491	17494	our	our	PRP$
2755	17495	17506	experiments	experiment	NNS
2756	17507	17511	were	be	VBD
2757	17520	17529	conducted	conduct	VBN
2758	17530	17532	at	at	IN
2759	17533	17540	similar	similar	JJ
2760	17541	17548	passage	passage	NN
2761	17549	17555	levels	level	NNS
2763	17557	17564	passage	passage	NN
2764	17565	17566	6	6	CD
2765	17567	17569	to	to	TO
2766	17570	17571	8	8	CD
2768	17573	17575	in	in	IN
2769	17584	17588	both	both	DT
2770	17589	17595	groups	group	NNS
2772	17597	17602	since	since	IN
2773	17603	17613	senescence	senescence	NN
2774	17614	17616	of	of	IN
2775	17617	17628	fibroblasts	fibroblast	NNS
2776	17629	17631	is	be	VBZ
2777	17632	17642	associated	associate	VBN
2778	17651	17655	with	with	IN
2779	17656	17657	a	a	DT
2780	17658	17663	shift	shift	NN
2781	17664	17668	from	from	IN
2782	17669	17672	the	the	DT
2783	17673	17685	biosynthesis	biosynthesis	NNS
2784	17686	17688	of	of	IN
2785	17689	17692	PGI	pgi	NNP
2786	17702	17703	2	2	CD
2787	17704	17706	to	to	TO
2788	17707	17710	TXA	txa	NNP
2789	17720	17721	2	2	CD
2791	17724	17726	24	24	CD
2792	17727	17729	25	25	CD
2795	17734	17736	It	it	PRP
2796	17737	17739	is	be	VBZ
2797	17740	17748	possible	possible	JJ
2798	17749	17753	that	that	IN
2799	17754	17757	the	the	DT
2800	17766	17776	difference	difference	NN
2801	17777	17781	seen	see	VBN
2802	17782	17784	in	in	IN
2803	17785	17788	our	our	PRP$
2804	17789	17794	study	study	NN
2805	17795	17802	between	between	IN
2806	17803	17809	HF-IPF	hf-ipf	NNP
2807	17810	17813	and	and	CC
2808	17814	17819	HF-NL	hf-nl	NNP
2809	17820	17825	could	could	MD
2810	17834	17840	result	result	VB
2811	17841	17845	from	from	IN
2812	17846	17855	comparing	compare	VBG
2813	17856	17867	fibroblasts	fibroblast	NNS
2814	17868	17870	of	of	IN
2815	17871	17880	different	different	JJ
2816	17881	17885	ages	age	NNS
2818	17887	17893	HF-IPF	hf-ipf	NNP
2819	17902	17907	might	might	MD
2820	17908	17912	have	have	VB
2821	17913	17917	been	be	VBN
2822	17918	17927	harvested	harvest	VBN
2823	17928	17932	from	from	IN
2824	17933	17941	fibrotic	fibrotic	JJ
2825	17942	17949	lesions	lesion	NNS
2826	17950	17955	where	where	WRB
2827	17964	17975	fibroblasts	fibroblast	NNS
2828	17976	17979	had	have	VBD
2829	17980	17990	previously	previously	RB
2830	17991	18000	undergone	undergo	VBN
2831	18001	18002	a	a	DT
2832	18003	18010	greater	greater	JJR
2833	18011	18017	number	number	NN
2834	18018	18020	of	of	IN
2835	18029	18033	cell	cell	NN
2836	18034	18043	divisions	division	NNS
2837	18044	18048	than	than	IN
2838	18049	18054	HF-NL	hf-nl	NNP
2840	18056	18064	obtained	obtain	VBN
2841	18065	18069	from	from	IN
2842	18070	18081	nonfibrotic	nonfibrotic	JJ
2843	18082	18087	lungs	lung	NNS
2845	18097	18105	Although	although	IN
2846	18106	18110	this	this	DT
2847	18111	18113	is	be	VBZ
2848	18114	18115	a	a	DT
2849	18116	18127	possibility	possibility	NN
2851	18129	18132	the	the	DT
2852	18133	18136	age	age	NN
2854	18137	18144	related	relate	VBN
2855	18145	18150	shift	shift	NN
2856	18151	18153	in	in	IN
2857	18154	18156	PG	pg	NNP
2858	18165	18175	production	production	NN
2859	18176	18179	has	have	VBZ
2860	18180	18184	only	only	RB
2861	18185	18189	been	be	VBN
2862	18190	18195	shown	show	VBN
2863	18196	18198	at	at	IN
2864	18199	18203	very	very	RB
2865	18204	18208	high	high	JJ
2866	18209	18213	cell	cell	NN
2867	18214	18222	passages	passage	NNS
2868	18231	18234	and	and	CC
2869	18235	18238	has	have	VBZ
2870	18239	18242	not	not	RB
2871	18243	18247	been	be	VBN
2872	18248	18258	documented	document	VBN
2873	18268	18270	in	in	IN
2874	18271	18275	vivo	vivo	NN
2876	18286	18288	We	we	PRP
2877	18289	18293	also	also	RB
2878	18294	18299	found	find	VBD
2879	18300	18304	that	that	IN
2880	18305	18309	both	both	DT
2881	18310	18316	HF-IPF	hf-ipf	NNP
2882	18317	18320	and	and	CC
2883	18321	18326	HF-NL	hf-nl	NNP
2884	18327	18330	had	have	VBD
2885	18331	18338	similar	similar	JJ
2886	18339	18342	PGE	pge	NNP
2887	18360	18361	2	2	CD
2888	18362	18372	production	production	NN
2889	18373	18375	at	at	IN
2890	18376	18384	baseline	baseline	NN
2892	18386	18389	and	and	CC
2893	18390	18391	a	a	DT
2894	18392	18399	similar	similar	JJ
2895	18408	18416	increase	increase	NN
2896	18417	18421	when	when	WRB
2897	18422	18432	stimulated	stimulate	VBN
2898	18433	18437	with	with	IN
2899	18438	18443	IL-1?	il-1?	NNP
2901	18445	18448	PGE	pge	NNP
2902	18458	18459	2	2	CD
2903	18460	18463	can	can	MD
2904	18464	18472	decrease	decrease	VB
2905	18473	18483	fibroblast	fibroblast	NN
2906	18484	18497	proliferation	proliferation	NN
2907	18506	18509	and	and	CC
2908	18510	18518	collagen	collagen	NN
2909	18519	18528	synthesis	synthesis	NN
2911	18530	18533	and	and	CC
2912	18534	18542	increase	increase	NN
2913	18543	18551	collagen	collagen	NN
2914	18552	18563	degradation	degradation	NN
2916	18574	18575	5	5	CD
2917	18576	18577	6	6	CD
2918	18578	18579	7	7	CD
2919	18580	18581	8	8	CD
2922	18594	18600	Recent	recent	JJ
2923	18601	18608	reports	report	NNS
2924	18609	18619	suggesting	suggest	VBG
2925	18620	18629	decreased	decrease	VBN
2926	18630	18635	COX-2	cox-2	NNP
2927	18636	18646	expression	expression	NN
2928	18647	18650	and	and	CC
2929	18659	18662	PGE	pge	NNP
2930	18672	18673	2	2	CD
2931	18674	18684	production	production	NN
2932	18685	18687	in	in	IN
2933	18688	18691	IPF	ipf	NNP
2934	18692	18703	fibroblasts	fibroblast	NNS
2935	18704	18708	have	have	VBP
2936	18717	18725	received	receive	VBN
2937	18726	18737	significant	significant	JJ
2938	18738	18747	attention	attention	NN
2940	18750	18752	12	12	CD
2941	18753	18755	20	20	CD
2942	18756	18758	21	21	CD
2945	18763	18765	In	in	IN
2946	18766	18769	our	our	PRP$
2947	18770	18775	study	study	NN
2948	18784	18786	we	we	PRP
2949	18787	18792	found	find	VBD
2950	18793	18797	that	that	IN
2951	18798	18802	both	both	DT
2952	18803	18808	COX-2	cox-2	NNP
2953	18809	18816	protein	protein	NN
2954	18817	18827	expression	expression	NN
2955	18828	18831	and	and	CC
2956	18832	18835	PGE	pge	NNP
2957	18845	18846	2	2	CD
2958	18847	18857	production	production	NN
2959	18858	18862	were	be	VBD
2960	18863	18874	upregulated	upregulated	JJ
2961	18875	18877	to	to	TO
2962	18878	18879	a	a	DT
2963	18888	18895	similar	similar	JJ
2964	18896	18902	degree	degree	NN
2965	18903	18905	in	in	IN
2966	18906	18909	IPF	ipf	NNP
2967	18910	18913	and	and	CC
2968	18914	18920	normal	normal	JJ
2969	18921	18925	lung	lung	NN
2970	18926	18937	fibroblasts	fibroblast	NNS
2972	18939	18941	We	we	PRP
2973	18950	18957	believe	believe	VBP
2974	18958	18962	that	that	IN
2975	18963	18974	differences	difference	NNS
2976	18975	18977	in	in	IN
2977	18978	18989	methodology	methodology	NN
2978	18990	18993	and	and	CC
2979	18994	19001	patient	patient	NN
2980	19010	19019	selection	selection	NN
2981	19020	19023	may	may	MD
2982	19024	19031	explain	explain	VB
2983	19032	19035	the	the	DT
2984	19036	19049	discrepancies	discrepancy	NNS
2985	19050	19054	with	with	IN
2986	19055	19060	other	other	JJ
2987	19061	19068	studies	study	NNS
2989	19078	19086	Vancheri	vancheri	NNP
2990	19087	19090	and	and	CC
2991	19091	19104	collaborators	collaborator	NNS
2993	19107	19109	20	20	CD
2995	19112	19117	found	find	VBD
2996	19118	19122	that	that	IN
2997	19131	19147	TNF-?-stimulated	tnf-?-stimulated	NNP
2998	19148	19156	fibrotic	fibrotic	JJ
2999	19157	19161	lung	lung	NN
3000	19162	19173	fibroblasts	fibroblast	NNS
3001	19174	19177	had	have	VBD
3002	19178	19187	decreased	decrease	VBN
3003	19196	19201	COX-2	cox-2	NNP
3004	19202	19212	expression	expression	NN
3005	19213	19216	and	and	CC
3006	19217	19220	PGE	pge	NNP
3007	19230	19231	2	2	CD
3008	19232	19242	production	production	NN
3010	19244	19247	but	but	CC
3011	19248	19252	they	they	PRP
3012	19253	19260	further	further	RBR
3013	19261	19267	showed	show	VBD
3014	19276	19280	that	that	IN
3015	19281	19286	these	these	DT
3016	19287	19295	findings	finding	NNS
3017	19296	19300	were	be	VBD
3018	19301	19302	a	a	DT
3019	19303	19309	result	result	NN
3020	19310	19312	of	of	IN
3021	19313	19322	decreased	decrease	VBD
3022	19323	19333	expression	expression	NN
3023	19342	19344	of	of	IN
3024	19345	19350	TNF-?	tnf-?	NNP
3025	19351	19360	receptors	receptor	NNS
3027	19362	19365	The	the	DT
3028	19366	19372	latter	latter	JJ
3029	19373	19380	finding	finding	NN
3030	19381	19386	would	would	MD
3031	19387	19392	argue	argue	VB
3032	19393	19400	against	against	IN
3033	19409	19410	a	a	DT
3034	19411	19418	primary	primary	JJ
3035	19419	19425	defect	defect	NN
3036	19426	19428	in	in	IN
3037	19429	19434	COX-2	cox-2	NNP
3038	19435	19445	expression	expression	NN
3040	19447	19452	since	since	IN
3041	19453	19455	no	no	DT
3042	19456	19461	other	other	JJ
3043	19470	19478	stimulus	stimulus	NN
3045	19480	19485	other	other	JJ
3046	19486	19490	than	than	IN
3047	19491	19496	TNF-?	tnf-?	NNP
3049	19498	19501	was	be	VBD
3050	19502	19508	tested	test	VBN
3052	19510	19512	In	in	IN
3053	19513	19520	another	another	DT
3054	19521	19526	study	study	NN
3056	19536	19549	Keerthisingam	keerthisingam	NNP
3057	19559	19561	et	et	CC
3058	19562	19565	al.	al.	NN
3060	19568	19570	21	21	CD
3062	19573	19581	reported	report	VBD
3063	19582	19586	that	that	IN
3064	19587	19595	fibrotic	fibrotic	JJ
3065	19604	19608	lung	lung	NN
3066	19609	19620	fibroblasts	fibroblast	NNS
3067	19621	19624	had	have	VBD
3068	19625	19634	decreased	decrease	VBN
3069	19635	19640	COX-2	cox-2	NNP
3070	19641	19651	expression	expression	NN
3071	19652	19655	and	and	CC
3072	19656	19659	PGE	pge	NNP
3073	19669	19670	2	2	CD
3074	19671	19681	production	production	NN
3075	19682	19684	in	in	IN
3076	19685	19693	response	response	NN
3077	19694	19696	to	to	TO
3078	19697	19701	TGF?	tgf?	NNP
3079	19710	19721	stimulation	stimulation	NN
3081	19723	19727	This	this	DT
3082	19728	19733	study	study	NN
3083	19734	19742	differed	differ	VBD
3084	19743	19747	from	from	IN
3085	19748	19752	ours	ours	PRP
3086	19753	19755	in	in	IN
3087	19756	19760	that	that	IN
3088	19761	19762	a	a	DT
3089	19771	19780	different	different	JJ
3090	19781	19789	stimulus	stimulus	NN
3091	19790	19793	was	be	VBD
3092	19794	19798	used	use	VBN
3094	19800	19802	Of	of	IN
3095	19803	19815	significance	significance	NN
3096	19816	19818	is	be	VBZ
3097	19819	19822	the	the	DT
3098	19823	19827	fact	fact	NN
3099	19836	19840	that	that	IN
3100	19841	19844	the	the	DT
3101	19845	19850	COX-2	cox-2	NNP
3102	19851	19855	gene	gene	NN
3103	19856	19858	is	be	VBZ
3104	19859	19864	known	know	VBN
3105	19865	19867	to	to	TO
3106	19868	19870	be	be	VB
3107	19871	19876	NF-?B	nf-?b	NNP
3108	19877	19886	dependent	dependent	JJ
3110	19888	19891	and	and	CC
3111	19900	19905	IL-1?	il-1?	NNP
3113	19907	19910	but	but	CC
3114	19911	19914	not	not	RB
3115	19915	19919	TGF?	tgf?	NNP
3117	19921	19923	is	be	VBZ
3118	19924	19925	a	a	DT
3119	19926	19932	potent	potent	JJ
3120	19933	19940	inducer	inducer	NN
3121	19941	19943	of	of	IN
3122	19944	19949	NF-?B	nf-?b	NNP
3123	19958	19968	activation	activation	NN
3125	19970	19975	Hence	hence	RB
3127	19977	19980	the	the	DT
3128	19981	19988	pathway	pathway	NN
3129	19989	19997	involved	involve	VBN
3130	19998	20000	in	in	IN
3131	20001	20004	the	the	DT
3132	20005	20014	induction	induction	NN
3133	20015	20017	of	of	IN
3134	20026	20029	the	the	DT
3135	20030	20035	COX-2	cox-2	NNP
3136	20036	20040	gene	gene	NN
3137	20041	20043	by	by	IN
3138	20044	20049	IL-1?	il-1?	NNP
3139	20050	20053	and	and	CC
3140	20054	20058	TGF?	tgf?	NNP
3141	20059	20062	may	may	MD
3142	20063	20065	be	be	VB
3143	20066	20075	different	different	JJ
3145	20085	20096	Furthermore	furthermore	RB
3147	20098	20099	a	a	DT
3148	20100	20111	significant	significant	JJ
3149	20112	20122	proportion	proportion	NN
3150	20123	20125	of	of	IN
3151	20126	20129	the	the	DT
3152	20130	20141	fibroblasts	fibroblast	NNS
3153	20150	20154	used	use	VBN
3154	20155	20157	in	in	IN
3155	20158	20161	the	the	DT
3156	20162	20167	study	study	NN
3157	20168	20170	by	by	IN
3158	20171	20184	Keerthisingam	keerthisingam	NNP
3159	20194	20196	et	et	CC
3160	20197	20200	al.	al.	NN
3162	20203	20205	21	21	CD
3164	20208	20212	were	be	VBD
3165	20213	20221	obtained	obtain	VBN
3166	20222	20226	from	from	IN
3167	20235	20243	patients	patient	NNS
3168	20244	20248	with	with	IN
3169	20249	20257	systemic	systemic	JJ
3170	20258	20267	sclerosis	sclerosis	NN
3172	20269	20274	which	which	WDT
3173	20275	20280	makes	make	VBZ
3174	20281	20286	their	their	PRP$
3175	20295	20305	fibroblast	fibroblast	NN
3176	20306	20316	population	population	NN
3177	20317	20321	more	more	RBR
3178	20322	20335	heterogeneous	heterogeneous	JJ
3180	20345	20352	Wilborn	wilborn	NNP
3181	20362	20364	et	et	CC
3182	20365	20368	al.	al.	NN
3184	20371	20373	12	12	CD
3186	20376	20380	also	also	RB
3187	20381	20389	reported	report	VBD
3188	20390	20391	a	a	DT
3189	20400	20409	decreased	decrease	VBN
3190	20410	20420	production	production	NN
3191	20421	20423	of	of	IN
3192	20424	20427	PGE	pge	NNP
3193	20437	20438	2	2	CD
3194	20439	20441	by	by	IN
3195	20442	20458	IL-1?-stimulated	il-1?-stimulated	NNP
3196	20459	20462	IPF	ipf	NNP
3197	20463	20474	fibroblasts	fibroblast	NNS
3199	20484	20487	due	due	JJ
3200	20488	20490	to	to	TO
3201	20491	20500	decreased	decrease	VBD
3202	20501	20506	COX-2	cox-2	NNP
3203	20507	20517	expression	expression	NN
3205	20520	20522	12	12	CD
3208	20527	20532	There	there	EX
3209	20533	20535	is	be	VBZ
3210	20536	20537	a	a	DT
3211	20546	20557	possibility	possibility	NN
3212	20558	20562	that	that	DT
3213	20563	20570	patient	patient	NN
3214	20571	20580	selection	selection	NN
3215	20581	20584	may	may	MD
3216	20585	20589	have	have	VB
3217	20590	20598	differed	differ	VBD
3218	20607	20614	between	between	IN
3219	20615	20618	the	the	DT
3220	20619	20622	two	two	CD
3221	20623	20630	studies	study	NNS
3223	20632	20639	However	however	RB
3225	20641	20643	we	we	PRP
3226	20644	20648	feel	feel	VBP
3227	20649	20656	certain	certain	JJ
3228	20657	20661	that	that	IN
3229	20662	20665	the	the	DT
3230	20674	20684	diagnostic	diagnostic	JJ
3231	20685	20693	accuracy	accuracy	NN
3232	20694	20696	of	of	IN
3233	20697	20700	our	our	PRP$
3234	20701	20708	patient	patient	NN
3235	20709	20719	population	population	NN
3236	20720	20723	was	be	VBD
3237	20724	20728	high	high	JJ
3239	20730	20733	due	due	JJ
3240	20742	20744	to	to	TO
3241	20745	20748	the	the	DT
3242	20749	20753	fact	fact	NN
3243	20754	20758	that	that	IN
3244	20759	20760	5	5	CD
3245	20761	20764	out	out	IN
3246	20765	20767	of	of	IN
3247	20768	20769	a	a	DT
3248	20770	20775	total	total	NN
3249	20776	20778	of	of	IN
3250	20779	20780	7	7	CD
3251	20781	20784	IPF	ipf	NNP
3252	20785	20793	subjects	subject	NNS
3253	20802	20810	included	include	VBN
3254	20811	20813	in	in	IN
3255	20814	20817	our	our	PRP$
3256	20818	20823	study	study	NN
3257	20824	20833	underwent	undergo	VBD
3258	20834	20838	lung	lung	NN
3259	20839	20854	transplantation	transplantation	NN
3260	20855	20859	with	with	IN
3261	20868	20880	confirmatory	confirmatory	NN
3262	20881	20890	pathology	pathology	NN
3263	20891	20898	results	result	NNS
3264	20899	20909	consistent	consistent	JJ
3265	20910	20914	with	with	IN
3266	20915	20918	IPF	ipf	NNP
3268	20920	20923	The	the	DT
3269	20932	20937	other	other	JJ
3270	20938	20939	2	2	CD
3271	20940	20948	subjects	subject	NNS
3272	20949	20952	had	have	VBD
3273	20953	20959	biopsy	biopsy	NN
3275	20960	20966	proven	prove	VBN
3276	20967	20970	IPF	ipf	NNP
3278	20972	20974	In	in	IN
3279	20975	20983	addition	addition	NN
3281	20985	20988	our	our	PRP$
3282	20997	21004	results	result	NNS
3283	21005	21009	were	be	VBD
3284	21010	21017	similar	similar	JJ
3285	21018	21022	when	when	WRB
3286	21023	21032	comparing	compare	VBG
3287	21033	21037	lung	lung	NN
3288	21038	21049	fibroblasts	fibroblast	NNS
3289	21058	21066	obtained	obtain	VBN
3290	21067	21071	from	from	IN
3291	21072	21073	5	5	CD
3292	21074	21082	subjects	subject	NNS
3293	21083	21087	with	with	IN
3294	21088	21096	advanced	advanced	JJ
3295	21097	21102	stage	stage	NN
3296	21103	21106	IPF	ipf	NNP
3297	21107	21111	with	with	IN
3298	21112	21117	those	those	DT
3299	21126	21128	of	of	IN
3300	21129	21130	2	2	CD
3301	21131	21139	subjects	subject	NNS
3302	21140	21142	at	at	IN
3303	21143	21145	an	an	DT
3304	21146	21153	earlier	earlier	JJR
3305	21154	21159	stage	stage	NN
3306	21160	21162	of	of	IN
3307	21163	21168	their	their	PRP$
3308	21169	21176	disease	disease	NN
3310	21178	21181	who	who	WP
3311	21182	21185	had	have	VBD
3312	21194	21202	received	receive	VBN
3313	21203	21205	no	no	DT
3314	21206	21213	therapy	therapy	NN
3316	21215	21223	Although	although	IN
3317	21224	21227	the	the	DT
3318	21228	21235	reasons	reason	NNS
3319	21236	21239	for	for	IN
3320	21240	21243	our	our	PRP$
3321	21244	21253	different	different	JJ
3322	21262	21269	results	result	NNS
3323	21270	21273	are	be	VBP
3324	21274	21281	unclear	unclear	JJ
3326	21283	21286	the	the	DT
3327	21287	21291	fact	fact	NN
3328	21292	21296	that	that	IN
3329	21297	21299	we	we	PRP
3330	21300	21305	found	find	VBD
3331	21306	21313	similar	similar	JJ
3332	21314	21319	COX-2	cox-2	NNP
3333	21328	21338	expression	expression	NN
3334	21339	21342	and	and	CC
3335	21343	21346	PGE	pge	NNP
3336	21356	21357	2	2	CD
3337	21358	21368	production	production	NN
3338	21369	21371	in	in	IN
3339	21372	21378	normal	normal	JJ
3340	21379	21382	and	and	CC
3341	21383	21386	IPF	ipf	NNP
3342	21387	21391	lung	lung	NN
3343	21400	21411	fibroblasts	fibroblast	NNS
3344	21412	21420	suggests	suggest	VBZ
3345	21421	21425	that	that	DT
3346	21426	21430	loss	loss	NN
3347	21431	21433	of	of	IN
3348	21434	21439	COX-2	cox-2	NNP
3349	21440	21450	expression	expression	NN
3350	21451	21453	is	be	VBZ
3351	21454	21457	not	not	RB
3352	21458	21459	a	a	DT
3353	21468	21477	universal	universal	JJ
3354	21478	21492	characteristic	characteristic	NN
3355	21493	21495	of	of	IN
3356	21496	21507	fibroblasts	fibroblast	NNS
3357	21508	21516	cultured	cultured	JJ
3358	21517	21521	from	from	IN
3359	21522	21525	the	the	DT
3360	21534	21539	lungs	lung	NNS
3361	21540	21542	of	of	IN
3362	21543	21551	subjects	subject	NNS
3363	21552	21556	with	with	IN
3364	21557	21560	IPF	ipf	NNP
3366	21584	21594	Conclusion	conclusion	NNP
3367	21603	21605	We	we	PRP
3368	21606	21610	have	have	VBP
3369	21611	21616	found	find	VBN
3370	21617	21621	that	that	WDT
3371	21622	21633	fibroblasts	fibroblast	NNS
3372	21634	21642	cultured	cultured	JJ
3373	21643	21647	from	from	IN
3374	21648	21654	normal	normal	JJ
3375	21655	21658	and	and	CC
3376	21667	21670	IPF	ipf	NNP
3377	21671	21676	human	human	JJ
3378	21677	21682	lungs	lung	NNS
3379	21683	21687	have	have	VBP
3380	21688	21689	a	a	DT
3381	21690	21701	significant	significant	JJ
3382	21702	21705	and	and	CC
3383	21706	21713	similar	similar	JJ
3384	21714	21723	induction	induction	NN
3385	21724	21726	of	of	IN
3386	21735	21738	the	the	DT
3387	21739	21744	COX-2	cox-2	NNP
3388	21745	21751	enzyme	enzyme	NN
3389	21752	21756	when	when	WRB
3390	21757	21767	stimulated	stimulate	VBN
3391	21768	21772	with	with	IN
3392	21773	21778	IL-1?	il-1?	NNP
3394	21780	21783	but	but	CC
3395	21784	21788	that	that	IN
3396	21789	21792	IPF	ipf	NNP
3397	21801	21812	fibroblasts	fibroblast	NNS
3398	21813	21821	produced	produce	VBD
3399	21822	21826	more	more	JJR
3400	21827	21838	thromboxane	thromboxane	NN
3401	21839	21842	and	and	CC
3402	21843	21846	had	have	VBD
3403	21847	21848	a	a	DT
3404	21857	21870	significantly	significantly	RB
3405	21871	21876	lower	lower	JJR
3406	21877	21889	prostacyclin	prostacyclin	NN
3408	21890	21901	thromboxane	thromboxane	NN
3409	21902	21907	ratio	ratio	NN
3411	21909	21911	We	we	PRP
3412	21920	21931	hypothesize	hypothesize	NN
3413	21932	21936	that	that	IN
3414	21937	21940	the	the	DT
3415	21941	21946	lower	lower	JJR
3416	21947	21950	PGI	pgi	NNP
3417	21960	21961	2	2	CD
3419	21963	21966	TXA	txa	NNP
3420	21976	21977	2	2	CD
3421	21978	21983	ratio	ratio	NN
3422	21984	21988	seen	see	VBN
3423	21989	21991	in	in	IN
3424	21992	21998	HF-IPF	hf-ipf	NNP
3425	21999	22002	may	may	MD
3426	22003	22005	be	be	VB
3427	22006	22007	a	a	DT
3428	22016	22026	phenotypic	phenotypic	JJ
3429	22027	22037	alteration	alteration	NN
3430	22038	22042	that	that	WDT
3431	22043	22048	plays	play	VBZ
3432	22049	22050	a	a	DT
3433	22051	22055	role	role	NN
3434	22056	22058	in	in	IN
3435	22059	22062	the	the	DT
3436	22063	22075	pathogenesis	pathogenesis	NNS
3437	22084	22086	of	of	IN
3438	22087	22090	IPF	ipf	NNP
3440	22114	22127	Abbreviations	abbreviations	NNP
3441	22136	22139	COX	cox	NNP
3443	22142	22156	cyclooxygenase	cyclooxygenase	NN
3445	22158	22160	HF	hf	NNP
3447	22163	22168	human	human	JJ
3448	22169	22180	fibroblasts	fibroblast	NNS
3450	22182	22184	NL	nl	NNP
3452	22195	22201	normal	normal	JJ
3453	22202	22207	lungs	lung	NNS
3455	22209	22212	IPF	ipf	NNP
3457	22215	22225	idiopathic	idiopathic	JJ
3458	22226	22235	pulmonary	pulmonary	JJ
3459	22236	22244	fibrosis	fibrosis	NNS
3461	22246	22249	IFN	ifn	NNP
3463	22260	22270	interferon	interferon	NN
3465	22272	22274	IL	il	NNP
3467	22277	22288	interleukin	interleukin	NN
3469	22290	22292	PG	pg	NNP
3471	22295	22308	prostaglandin	prostaglandin	NN
3473	22310	22312	TX	tx	NNP
3475	22323	22334	thromboxane	thromboxane	NN
3477	22336	22339	PGI	pgi	NNP
3478	22349	22350	2	2	CD
3480	22353	22365	prostacyclin	prostacyclin	NN
